

Supporting Information

**Cu(I)- and Au(I)-Catalyzed Regioselective Oxidations of Diynes: Divergent
Synthesis of N-Heterocycles**

Wen-Bo Shen,^{*a} Ting-Ting Zhang,^a Meng Zhang,^a Jing-Jing Wu,^b Xiao-Lei Jiang,^a
Guang-Xin Ru,^{*a} Guang-Qin Gao,^a and Xiu-Hong Zhu^a

^aCollege of Sciences and College of Forestry, Henan Agricultural University, Zhengzhou
450002, China

^bDepartment of Library, Qingdao Agricultural University, Qingdao 266109, China

Content	Page Number
General Information	S2
More Reaction Condition and Mechanism Studies	S3
Preparation of Starting Materials	S5
General Procedure: Copper Catalysis and Gold Catalysis	S7
Synthetic Applications	S39
X-Ray Crystallographic Data	S42
NMR Spectra	S45

General Information. Ethyl acetate (ACS grade), hexanes (ACS grade) and anhydrous 1,2-dichloroethane (ACS grade) were obtained commercially and used without further purification. Methylene chloride, tetrahydrofuran and diethyl ether were purified according to standard methods unless otherwise noted. Commercially available reagents were used without further purification. Reactions were monitored by thin layer chromatography (TLC) using silicycle pre-coated silica gel plates. Flash column chromatography was performed over silica gel (300-400 mesh). Infrared spectra were recorded on a Nicolet iS 10 spectrometer as thin film and are reported in reciprocal centimeter (cm^{-1}). Mass spectra were recorded with Micromass Q-Exactive Focus mass spectrometer using electron spray ionization.


^1H NMR spectra were recorded on a Bruker AV-400 spectrometer in chloroform- d_3 . Chemical shifts are reported in ppm with the internal TMS signal at 0.0 ppm as a standard. The data is being reported as (s = singlet, d = doublet, t = triplet, m = multiplet or unresolved, brs = broad singlet, coupling constant(s) in Hz, integration).

^{13}C NMR spectra were recorded on on a Bruker AV-400 spectrometer in chloroform- d_3 . Chemical shifts are reported in ppm with the internal chloroform signal at 77.0 ppm as a standard.


More Reaction Condition and Mechanism Studies

1. **3a** and **3aa** could not be converted to each other:


3aa could not be converted into **3a** under Cu catalysis: only **3aa** was recovered.



3a could not be converted into **3aa** under Au catalysis: only **3a** was recovered.




2. Other noble metals such as IPrAuCl/AgNTf₂, XPhosAuCl/AgNTf₂ and AgNTf₂, and Brønsted acids did not catalyze this reaction. These reactions only gave a complicated mixture of products.



Entry	Cat. (x mol %)	Oxidant	T (°C)	Yield [%]	
				3a	3aa
1	IPrAuCl/AgNTf ₂ (5)	2a	80	11	68
2	XPhosAuCl/AgNTf ₂ (5)	2a	80	25	33
3	AgNTf ₂ (5)	2a	80	33	18
4	MsOH (10)	2a	80	<1	<1
5	TsOH (10)	2a	80	<1	<1
6	CF ₃ COOH (10)	2a	80	<1	<1
7	TfOH (10)	2a	80	<1	<1
8	HNTf ₂ (10)	2a	80	<1	<1

3. Optimization of reaction conditions for the oxidative cyclization of diyne **4a**, please see as followed:^a




Entry	Cat. (x mol %)	Reaction conditions	Yield [%] ^b	
			5a	5aa
1	Cu(CH ₃ CN) ₄ BF ₄ (10)	DCE, 80 °C, 12 h	7	16
2	Cu(CH ₃ CN) ₄ PF ₆ (10)	DCE, 80 °C, 4.5 h	12	14
3	CuOTf (10)	DCE, 80 °C, 25 h	8	10
4	Cu(OTf) ₂ (10)	DCE, 80 °C, 6.5 h	10	20
5	Ph ₃ PAuCl/AgNTf ₂ (5)	DCE, 80 °C, 2 h	28	5
6	Ph ₃ PAuCl/AgNTf ₂ (5)	PhCl, 80 °C, 1.5 h	71	12
7	Ph ₃ PAuCl/AgNTf ₂ (5)	PhCF ₃ , 80 °C, 1.5 h	78	10
8	Ph ₃ PAuCl/AgNTf ₂ (5)	TCE, 80 °C, 1.5 h	63	14
9	Ph ₃ PAuCl/AgNTf ₂ (5)	PhCF ₃ , 60 °C, 1.5 h	78	11
10	IPrAuCl/AgNTf ₂ (5)	PhCF ₃ , 60 °C, 1.0 h	67	9
11	XPhosAuCl/AgNTf ₂ (5)	PhCF ₃ , 60 °C, 1.0 h	51	6
12^c	Ph₃PAuCl/AgNTf₂ (5)	PhCF₃, 60 °C, 1.0 h	80	5

^a Reaction conditions: **4a** (0.1 mmol), **2a** (0.12 mmol), catalyst (5-10 mol %), 0.05 M, in vials. ^b Measured by ¹H NMR using diethyl phthalate as the internal standard. ^c 10 mol % NaBARF was added.

Representative synthetic procedures for the preparation of amide-tethered diynes

1a-1u:




(A): Acyl chloride (12.0 mmol) was slowly added to a solution of 2-iodoaniline (10.0 mmol) in 20.0 mL dry THF at room temperature via dropping funnel. The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by TLC. The reaction typically took 24 h. Upon completion, EtOAc (30 mL) was added, and the mixture was washed with 5% NaHCO₃, brine, dried over MgSO₄, and concentrated under reduced pressure to yield the crude iodobenzene **s1**, which was then used in the next step without purification.¹

(B): Add Pd(PPh₃)₂Cl₂ (0.2 mmol, 140.4 mg), CuI (0.4 mmol, 76.0 mg) and triethylamine (20.0 mmol, 2020.0 mg) to a solution of the *N*-sulfonyl propargyl amine (10.0 mmol) and iodobenzene **s1** (10.0 mmol) in THF (30.0 mL) at room temperature. The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by TLC. The reaction typically took 12 h. Upon completion, the reaction crude was filtered through a Celite plug and concentrated under vacuum, and the residue was purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired substrates **s2**.²

(C): To a mixture of **s2** (3.0 mmol), K₃PO₄ (12.0 mmol, 2544.0 mg), CuI (1.5 mmol, 285.0 mg), and DMEDA (3.0 mmol, 264.0 mg) in the reaction vial was added a solution of a respective brominated alkyne (3.3 mmol) in toluene. The reaction mixture was

stirred at room temperature and the progress of the reaction was monitored by TLC. The reaction typically took 3 h. Upon completion, the reaction crude was filtered through a Celite plug and concentrated under vacuum, and the residue was purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired enynamide substrates **1a-1u**.²


Representative synthetic procedures for the preparation of diynes 4a-4o:



(D): Add propargyl bromide (10.0 mmol) to a solution of the PGNHBoc (10.0 mmol) and potassium carbonate (16.0 mmol, 2208.0 mg) in DMF (15.0 mL) at room temperature. The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by TLC. The reaction typically took 3 h. Upon completion, the reaction crude was filtered through a Celite plug and concentrated under vacuum, and the residue was added into a solution of the trifluoroacetic acid (80.0 mmol, 9120.0 mg) in DCM (15.0 mL) at room temperature. The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by TLC. The reaction typically took 12 h. Upon completion, the reaction crude was concentrated under vacuum, and the residue was purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired substrates **s3**.³

(E): To a mixture of **s3** (3.0 mmol), K_3PO_4 (12.0 mmol, 2544.0 mg), CuI (1.5 mmol, 285.0 mg), and DMEDA (3.0 mmol, 264.0 mg) in the reaction vial was added a solution of a respective brominated alkyne (3.3 mmol) in toluene. The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by TLC. The reaction typically took 3 h. Upon completion, the reaction crude was filtered through a Celite plug and concentrated under vacuum, and the residue was purified by


chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired enynamide substrates **4a-4o**.²



General procedure for the synthesis of pyrroles **3**:

3,5-Dichloropyridine *N*-oxide **2a** (0.3 mmol, 49.2 mg) and $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (0.02 mmol, 6.3 mg) were added in this order to the amide-tethered diynes **1** (0.2 mmol) in DCE (4.0 mL) at room temperature. The reaction mixture was stirred at 80 °C (80 °C, heating mantle temperature) and the progress of the reaction was monitored by TLC. The reaction typically took 2 h. Upon completion, the mixture was then concentrated and the residue was purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired product **3**.

N-(2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**3a**)



3a


The reaction was conducted with *N*-(2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1a**, 0.2 mmol, 101.0 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature).

Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3a** (81.8 mg, 79%) as a pale yellow oil.

The reaction was conducted with *N*-(2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1a**, 1.0 mmol, 505.0 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 1.5 mmol, 246.0 mg), and Cu(CH₃CN)₄BF₄ (0.1 mmol, 31.5 mg) in DCE (20.0 mL) at 80 °C (80 °C, oil bath temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3a** (369.9 mg, 71%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.85 (s, 1H), 8.81 (d, *J* = 8.4 Hz, 1H), 7.97 (d, *J* = 8.0 Hz, 2H), 7.83 (d, *J* = 8.1 Hz, 2H), 7.78 (d, *J* = 7.9 Hz, 1H), 7.59 (t, *J* = 7.9 Hz, 1H), 7.52 – 7.42 (m, 4H), 7.34 (d, *J* = 8.1 Hz, 2H), 7.30 – 7.24 (m, 6H), 7.05 (t, *J* = 7.6 Hz, 1H), 2.42 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.3, 166.0, 146.2, 140.7, 134.8(4), 134.8(0), 134.5, 133.5, 132.2, 132.0, 130.4, 130.0, 128.7, 128.5, 128.1, 127.5, 127.4(1), 127.3(8), 126.6, 126.2, 124.2, 122.4, 121.2, 119.1, 21.7; IR (neat): 3284 (br), 2924, 1727, 1678, 1603, 1581, 1494, 1448, 1377, 1305, 1189, 1174, 1067, 906, 669; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₁H₂₅N₂O₄S 521.1530, found 521.1524.

***N*-(2-(5-oxo-4-phenyl-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3aa)**




3aa

¹H NMR (400 MHz, CDCl₃) δ 11.33 (s, 1H), 8.04 (d, *J* = 7.3 Hz, 1H), 7.21 – 7.15 (m, 4H), 6.73 – 6.58 (m, 5H), 6.50 – 6.32 (m, 7H), 5.97 (d, *J* = 6.7 Hz, 1H), 3.93 (s, 2H), 1.57 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 196.3, 166.2, 166.1, 147.6, 145.7, 142.2, 137.1, 136.0, 134.7, 134.3, 133.3, 132.4, 129.9, 129.0, 128.9, 128.6, 128.4, 127.5, 122.7, 120.8, 119.7, 50.7, 21.7; IR (neat): 3284 (br), 2924, 1727, 1683, 1624, 1582, 1494, 1449, 1367,

1241, 1183, 1158, 1090, 965, 665; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{31}H_{25}N_2O_5S$ 537.1479, found 537.1477.

***N*-(2-(4-phenyl-1-(phenylsulfonyl)-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3b)**




3b

The reaction was conducted with *N*-(2-(3-(*N*-(phenylethynyl)phenylsulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1b**, 0.2 mmol, 98.2 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and $Cu(CH_3CN)_4BF_4$ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3b** (86.0 mg, 85%) as a pale yellow oil.

1H NMR (400 MHz, $CDCl_3$) δ 11.87 (s, 1H), 8.82 (d, $J = 8.4$ Hz, 1H), 8.03 – 7.95 (m, 4H), 7.77 (d, $J = 7.8$ Hz, 1H), 7.66 – 7.42 (m, 8H), 7.32 – 7.25 (m, 6H), 7.05 (t, $J = 7.6$ Hz, 1H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 194.3, 166.0, 140.8, 137.9, 134.9, 134.7, 134.4, 133.6, 132.1, 132.0, 130.1, 129.8, 128.7, 128.5, 128.1, 127.5, 127.4, 127.3, 126.8, 126.1, 124.1, 122.4, 121.2, 119.1; IR (neat): 3280 (br), 2924, 1727, 1678, 1629, 1581, 1525, 1448, 1378, 1304, 1174, 1090, 1068, 755, 605; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{30}H_{23}N_2O_4S$ 507.1373, found 507.1370.

***N*-(2-(1-((4-bromophenyl)sulfonyl)-4-phenyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3c)**




3c

The reaction was conducted with *N*-(2-(3-((4-bromo-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1c**, 0.2 mmol, 113.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3c** (68.4 mg, 58%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.85 (s, 1H), 8.81 (d, *J* = 8.4 Hz, 1H), 7.98 (d, *J* = 7.6 Hz, 2H), 7.81 (d, *J* = 7.0 Hz, 2H), 7.75 (d, *J* = 7.9 Hz, 1H), 7.70 (d, *J* = 7.1 Hz, 2H), 7.59 (t, *J* = 7.9 Hz, 1H), 7.53 – 7.43 (m, 4H), 7.29 – 7.26 (m, 6H), 7.05 (t, *J* = 7.6 Hz, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 194.2, 166.0, 140.8, 136.8, 134.9, 134.4, 133.5, 133.2, 132.0, 131.9, 130.5, 130.3, 128.8, 128.7, 128.5, 128.1, 127.7, 127.4, 127.2, 125.9, 124.1, 122.5, 121.3, 118.9; IR (neat): 3311 (br), 2925, 1728, 1679, 1603, 1580, 1448, 1392, 1305, 1265, 1185, 1067, 1009, 906, 745; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₀H₂₂BrN₂O₄S 585.0478, found 585.0474.

N-(2-(1-(methylsulfonyl)-4-phenyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**3d**)




3d

The reaction was conducted with *N*-(2-(3-(*N*-(phenylethynyl)methylsulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1d**, 0.2 mmol, 85.7 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3d** (64.9 mg, 73%) as a yellow solid (mp 236-238 °C).

¹H NMR (400 MHz, CDCl₃) δ 11.93 (s, 1H), 8.84 (d, *J* = 8.4 Hz, 1H), 8.01 (d, *J* = 7.3 Hz, 2H), 7.79 (d, *J* = 7.8 Hz, 1H), 7.60 – 7.45 (m, 5H), 7.32 – 7.25 (m, 6H), 7.03 (t, *J* = 7.6

Hz, 1H), 3.28 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 194.5, 165.9, 140.9, 135.0, 134.5, 133.6, 132.0(2), 131.9(9), 130.2, 128.8, 128.6, 128.1, 127.7, 127.4, 127.0, 125.6, 123.9, 122.4, 121.2, 118.8, 43.3; IR (neat): 3265 (br), 2926, 1670, 1602, 1581, 1529, 1508, 1447, 1361, 1226, 1173, 1156, 1071, 904, 699; HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{25}\text{H}_{21}\text{N}_2\text{O}_4\text{S}$ 445.1217, found 445.1208.

***N*-(2-(4-(4-fluorophenyl)-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3e)**




3e

The reaction was conducted with *N*-(2-(3-(*N*-(4-fluorophenyl)ethynyl)methylsulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1e**, 0.2 mmol, 104.6 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3e** (99.9 mg, 92%) as a pale yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 11.78 (s, 1H), 8.80 (d, $J = 8.5$ Hz, 1H), 7.97 (d, $J = 7.9$ Hz, 2H), 7.83 (d, $J = 8.2$ Hz, 2H), 7.77 (d, $J = 7.9$ Hz, 1H), 7.61 (t, $J = 7.9$ Hz, 1H), 7.53 – 7.43 (m, 4H), 7.35 (d, $J = 7.9$ Hz, 2H), 7.26 – 7.23 (m, 3H), 7.08 (t, $J = 7.6$ Hz, 1H), 7.01 – 6.96 (m, 2H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 194.1, 166.0, 162.2 (d, $J = 245.0$ Hz), 146.2, 140.7, 134.9, 134.8, 134.4, 133.4, 132.0, 130.4, 129.8 (d, $J = 8.0$ Hz), 129.0, 128.7, 128.3 (d, $J = 3.0$ Hz), 127.4, 126.4, 124.3, 122.5, 121.4, 119.1, 115.5 (d, $J = 22.0$ Hz), 21.7; IR (neat): 3285 (br), 2924, 1727, 1681, 1602, 1581, 1511, 1448, 1377, 1295, 1175, 1069, 1007, 967, 668; HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{24}\text{FN}_2\text{O}_4\text{S}$ 539.1435, found 539.1425.

***N*-(2-(4-(4-chlorophenyl)-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3f)**




3f

The reaction was conducted with *N*-(2-(3-((*N*-((4-chlorophenyl)ethynyl)-4-methylphenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1f**, 0.2 mmol, 107.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3f** (87.1 mg, 79%) as a pale yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 11.76 (s, 1H), 8.81 (d, $J = 8.5$ Hz, 1H), 7.96 (d, $J = 7.2$ Hz, 2H), 7.84 – 7.78 (m, 3H), 7.63 (t, $J = 8.0$ Hz, 1H), 7.52 – 7.44 (m, 4H), 7.35 (d, $J = 7.7$ Hz, 2H), 7.28 – 7.21 (m, 2H), 7.10 (t, $J = 7.3$ Hz, 1H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 194.0, 166.0, 146.3, 140.7, 134.9, 134.7, 134.5, 133.5, 133.4, 132.0, 130.8, 130.5, 129.4, 128.9, 128.8, 128.7, 127.4, 126.6, 126.4, 124.3, 122.6, 121.5, 119.3, 21.7; IR (neat): 3317 (br), 2921, 1679, 1628, 1603, 1581, 1508, 1448, 1382, 1295, 1262, 1174, 1069, 906, 669; HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{31}\text{H}_{24}\text{ClN}_2\text{O}_4\text{S}$ 555.1140, found 555.1131.

***N*-(2-(4-(4-bromophenyl)-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3g)**




3g

The reaction was conducted with *N*-(2-(3-((*N*-((4-bromophenyl)ethynyl)-4-methylphenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1g**, 0.2 mmol, 116.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3g** (102.1 mg, 85%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.76 (s, 1H), 8.81 (d, *J* = 8.5 Hz, 1H), 7.96 (d, *J* = 7.3 Hz, 2H), 7.84 – 7.78 (m, 3H), 7.63 (t, *J* = 7.6 Hz, 1H), 7.53 – 7.42 (m, 6H), 7.35 (d, *J* = 7.9 Hz, 2H), 7.30 – 7.26 (m, 1H), 7.16 (d, *J* = 7.4 Hz, 2H), 7.10 (t, *J* = 7.6 Hz, 1H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 193.9, 166.0, 146.3, 140.7, 134.9, 134.7, 134.4, 133.4, 132.0, 131.6, 131.2, 130.5, 129.8, 128.9, 128.8, 127.4(2), 127.4(0), 126.6, 126.3, 124.3, 122.6, 121.6, 121.5, 119.3, 21.7; IR (neat): 3287 (br), 2923, 1671, 1623, 1603, 1580, 1509, 1494, 1378, 1297, 1253, 1173, 1069, 904, 664; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₁H₂₄BrN₂O₄S 599.0635, found 599.0628.

***N*-(2-(1-tosyl-4-(4-(trifluoromethyl)phenyl)-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3h)**




3h

The reaction was conducted with *N*-(2-(3-((4-methyl-*N*-((4-(trifluoromethyl)phenyl)ethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1h**, 0.2 mmol, 114.6 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3h** (88.4 mg, 75%) as a pale yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 11.73 (s, 1H), 8.81 (d, $J = 8.3$ Hz, 1H), 7.96 (d, $J = 7.0$ Hz, 2H), 7.85 – 7.80 (m, 3H), 7.63 (t, $J = 7.7$ Hz, 1H), 7.57 – 7.35 (m, 11H), 7.11 (t, $J = 7.5$ Hz, 1H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 193.8, 166.0, 146.4, 140.7, 135.0, 134.6, 134.4, 133.3, 132.0, 130.5, 128.8, 128.7, 128.4, 127.5, 127.4, 126.8, 126.3, 125.42 (q, $J = 3.7$ Hz), 124.3, 122.6, 121.5, 119.9, 21.7; IR (neat): 3288 (br), 2926, 1728, 1682, 1627, 1581, 1521, 1494, 1376, 1325, 1265, 1173, 1068, 906, 672; HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{32}\text{H}_{24}\text{F}_3\text{N}_2\text{O}_4\text{S}$ 589.1403, found 589.1395.

***N*-(2-(4-(*p*-tolyl)-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3i)**




3i

The reaction was conducted with *N*-(2-(3-((4-methyl-*N*-(*p*-tolylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1i**, 0.2 mmol, 103.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3i** (77.4 mg, 72%) as a pale yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 11.83 (s, 1H), 8.81 (d, $J = 8.4$ Hz, 1H), 7.97 (d, $J = 7.4$ Hz, 2H), 7.83 – 7.78 (m, 3H), 7.60 (t, $J = 7.9$ Hz, 1H), 7.51 – 7.43 (m, 4H), 7.34 (d, $J = 7.2$ Hz, 2H), 7.27 – 7.26 (m, 1H), 7.18 – 7.16 (m, 2H), 7.10 – 7.06 (m, 3H), 2.42 (s, 3H), 2.32 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 194.4, 166.0, 146.1, 140.7, 137.3, 134.9, 134.7, 134.5, 133.6, 131.9, 130.4, 130.0, 129.2, 128.7, 127.9, 127.4(4), 127.3(6), 126.6, 126.2, 124.4, 122.5, 121.3, 118.8, 21.7, 21.2; IR (neat): 3279 (br), 2922, 1732, 1679, 1629, 1581, 1517, 1448, 1378, 1305, 1264, 1189, 1069, 967, 618; HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{32}\text{H}_{27}\text{N}_2\text{O}_4\text{S}$ 535.1686, found 535.1677.

***N*-2-(4-(4-methoxyphenyl)-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**3j**)**




3j

The reaction was conducted with *N*-2-(3-((*N*-((4-methoxyphenyl)ethynyl)-4-methylphenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1j**, 0.2 mmol, 107.0 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3j** (75.3 mg, 68%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.85 (s, 1H), 8.81 (d, *J* = 8.4 Hz, 1H), 7.98 (d, *J* = 7.9 Hz, 2H), 7.83 – 7.77 (m, 3H), 7.60 (t, *J* = 7.8 Hz, 1H), 7.51 – 7.45 (m, 4H), 7.34 (d, *J* = 7.3 Hz, 2H), 7.27 – 7.20 (m, 3H), 7.07 (t, *J* = 7.0 Hz, 1H), 6.83 (d, *J* = 6.8 Hz, 2H), 3.78 (s, 3H), 2.42 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.5, 166.0, 159.1, 146.1, 140.7, 134.9, 134.8, 134.5, 133.6, 132.0, 130.4, 129.7, 129.3, 128.7, 127.4(3), 127.3(6), 126.6, 126.2, 124.6, 124.3, 122.5, 121.2, 118.5, 113.9, 55.2, 21.7; IR (neat): 3280 (br), 2925, 1727, 1679, 1628, 1580, 1514, 1493, 1377, 1295, 1249, 1174, 1037, 906, 670; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₂H₂₇N₂O₅S 551.1635, found 551.1625.

***N*-2-(4-(thiophen-3-yl)-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**3k**)**




3k

The reaction was conducted with *N*-(2-(3-((4-methyl-*N*-(thiophen-3-ylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1k**, 0.2 mmol, 102.2 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3k** (90.2 mg, 86%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.86 (s, 1H), 8.82 (d, *J* = 8.4 Hz, 1H), 8.01 (d, *J* = 7.3 Hz, 2H), 7.81 (d, *J* = 8.2 Hz, 2H), 7.74 (d, *J* = 7.8 Hz, 1H), 7.61 (t, *J* = 7.9 Hz, 1H), 7.55 – 7.43 (m, 4H), 7.38 – 7.32 (m, 4H), 7.26 (t, *J* = 3.9 Hz, 1H), 7.10 – 7.07 (m, 2H), 2.41 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.4, 165.9, 146.2, 140.7, 134.8(2), 134.7(5), 134.5, 133.6, 132.3, 132.0, 130.4, 128.8, 127.7, 127.4, 127.3, 126.5, 126.4, 125.6, 124.5, 124.4, 122.7, 122.5, 121.3, 119.0, 21.7; IR (neat): 3284 (br), 2922, 1727, 1680, 1628, 1581, 1524, 1494, 1448, 1327, 1207, 1135, 1070, 969, 666; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₉H₂₃N₂O₄S₂ 527.1094, found 527.1083.

N-(2-(4-styryl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**3l**)




3l

The reaction was conducted with *N*-(2-(3-((4-methyl-*N*-(4-phenylbut-3-en-1-yn-1-yl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1l**, 0.2 mmol, 106.2 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3l** (67.2 mg, 61%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.66 (s, 1H), 8.80 (d, *J* = 8.4 Hz, 1H), 8.01 (d, *J* = 7.7 Hz, 2H), 7.85 – 7.79 (m, 3H), 7.66 (t, *J* = 7.9 Hz, 1H), 7.53 – 7.41 (m, 7H), 7.36 – 7.26 (m, 6H), 7.19 (t, *J* = 7.6 Hz, 1H), 6.95 (d, *J* = 16.5 Hz, 1H), 2.41 (s, 3H); ¹³C NMR (100

MHz, CDCl₃) δ 193.9, 165.9, 146.2, 140.2, 137.0, 134.7, 134.5, 134.4, 132.8, 132.0, 130.6, 130.4, 128.8, 128.6, 127.8, 127.5, 127.3(9), 127.3(5), 127.2, 126.5, 126.3, 125.1, 122.7, 121.7, 119.0, 117.5, 21.7; IR (neat): 3318 (br), 2956, 1725, 1679, 1624, 1579, 1521, 1494, 1448, 1378, 1297, 1119, 1068, 967, 672; HRMS (ESI) m/z : [M + H]⁺ calcd for C₃₃H₂₇N₂O₄S 547.1686, found 547.1678.

***N*-(4-chloro-2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3m)**




3m

The reaction was conducted with *N*-(4-chloro-2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1m**, 0.2 mmol, 107.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3m** (61.8 mg, 56%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.71 (s, 1H), 8.78 (d, *J* = 9.0 Hz, 1H), 7.96 (d, *J* = 7.7 Hz, 2H), 7.86 (d, *J* = 7.2 Hz, 2H), 7.65 – 7.59 (m, 1H), 7.55 – 7.44 (m, 5H), 7.37 (d, *J* = 7.7 Hz, 2H), 7.30 – 7.22 (m, 6H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 193.1, 165.8, 146.3, 139.2, 134.8, 134.3, 134.2, 132.8, 132.2, 132.0, 130.5, 130.0, 128.8, 128.5, 128.2, 127.6, 127.4, 126.4, 126.2, 125.2, 122.6, 119.3, 21.7; IR (neat): 3287 (br), 2923, 1729, 1683, 1632, 1577, 1510, 1492, 1375, 1287, 1173, 1112, 1067, 967, 669; HRMS (ESI) m/z : [M + H]⁺ calcd for C₃₁H₂₄ClN₂O₄S 555.1140, found 555.1141.

***N*-(4-bromo-2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3n)**




3n

The reaction was conducted with *N*-(4-bromo-2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1n**, 0.2 mmol, 116.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3n** (72.3 mg, 60%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.73 (s, 1H), 8.73 (d, *J* = 9.0 Hz, 1H), 7.96 (d, *J* = 7.2 Hz, 2H), 7.86 (d, *J* = 7.1 Hz, 2H), 7.79 – 7.73 (m, 1H), 7.62 (d, *J* = 8.9 Hz, 1H), 7.56 – 7.44 (m, 4H), 7.37 (d, *J* = 7.5 Hz, 2H), 7.30 – 7.22 (m, 6H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 193.0, 165.8, 146.3, 139.6, 137.2, 135.7, 134.8, 134.1, 132.2, 132.0, 130.5, 130.0, 128.8, 128.5, 128.2, 127.6, 127.4, 126.4, 126.1, 125.4, 122.8, 119.3, 114.7, 21.7; IR (neat): 3286 (br), 2922, 1729, 1682, 1630, 1597, 1510, 1492, 1393, 1375, 1295, 1173, 1089, 966, 669; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₁H₂₄BrN₂O₄S 599.0635, found 599.0636.

***N*-(4-methyl-2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3o)**




3o

The reaction was conducted with *N*-(4-methyl-2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1o**, 0.2 mmol, 103.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature).

Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3o** (66.3 mg, 62%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.75 (s, 1H), 8.68 (d, *J* = 8.6 Hz, 1H), 7.98 (d, *J* = 8.0 Hz, 2H), 7.84 (d, *J* = 7.0 Hz, 2H), 7.51 – 7.43 (m, 5H), 7.39 – 7.34 (m, 3H), 7.30 – 7.26 (m, 6H), 2.44 (s, 3H), 2.24 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.4, 165.8, 146.2, 138.3, 135.5, 135.0, 134.6, 133.9, 132.3, 132.0, 131.9, 130.4, 130.0, 128.7, 128.5, 128.1, 127.5, 127.4, 126.8, 126.1, 124.1, 121.2, 119.0, 21.7, 20.7; IR (neat): 3290 (br), 2923, 1727, 1679, 1628, 1590, 1519, 1450, 1371, 1304, 1263, 1188, 1090, 968, 669; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₂H₂₇N₂O₄S 535.1686, found 535.1688.

4-fluoro-*N*-(2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**3p**)




3p

The reaction was conducted with 4-fluoro-*N*-(2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1p**, 0.2 mmol, 104.6 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3p** (85.6 mg, 79%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.87 (s, 1H), 8.78 (d, *J* = 8.3 Hz, 1H), 8.01 – 7.98 (m, 2H), 7.84 (d, *J* = 6.8 Hz, 2H), 7.79 (d, *J* = 7.9 Hz, 1H), 7.60 (t, *J* = 7.9 Hz, 1H), 7.50 – 7.46 (m, 1H), 7.35 (d, *J* = 7.4 Hz, 2H), 7.30 – 7.26 (m, 6H), 7.14 – 7.05 (m, 3H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.5, 164.3 (d, *J* = 104.0 Hz), 146.2, 140.7, 134.9, 133.6, 132.2, 130.4, 130.0, 129.9 (d, *J* = 9.0 Hz), 128.5, 128.1, 127.5, 127.4, 126.5, 126.2, 124.1, 122.5, 121.2, 119.2, 115.8 (d, *J* = 22.0 Hz), 21.7; IR (neat): 3324 (br), 2922, 1731, 1680, 1628, 1530, 1504, 1445, 1377, 1293, 1174, 1160, 1067, 967, 669; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₁H₂₄FN₂O₄S 539.1435, found 539.1436.

4-chloro-*N*-(2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**3q**)




3q

The reaction was conducted with 4-chloro-*N*-(2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1q**, 0.2 mmol, 107.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3q** (77.8 mg, 70%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.90 (s, 1H), 8.78 (d, *J* = 8.3 Hz, 1H), 7.91 (d, *J* = 6.1 Hz, 2H), 7.85 – 7.79 (m, 3H), 7.60 (t, *J* = 7.3 Hz, 1H), 7.52 – 7.48 (m, 1H), 7.41 (d, *J* = 6.2 Hz, 2H), 7.35 (d, *J* = 7.8 Hz, 2H), 7.30 – 7.25 (m, 6H), 7.07 (t, *J* = 6.7 Hz, 1H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.4, 164.8, 146.2, 140.6, 138.3, 134.9, 134.8, 133.6, 132.9, 132.2, 130.4, 130.0, 129.0, 128.9, 128.5, 128.1, 127.5, 127.4, 126.5, 126.2, 124.1, 122.6, 121.2, 119.1, 21.7; IR (neat): 3278 (br), 2924, 1732, 1682, 1628, 1594, 1528, 1490, 1378, 1294, 1174, 1067, 1013, 967, 669; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₁H₂₄ClN₂O₄S 555.1140, found 555.1142.

4-bromo-*N*-(2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**3r**)




3r

The reaction was conducted with 4-bromo-*N*-(2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1r**, 0.2 mmol,

116.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3r** (71.6 mg, 60%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.90 (s, 1H), 8.78 (d, *J* = 8.3 Hz, 1H), 7.85 – 7.79 (m, 5H), 7.60 (t, *J* = 8.8 Hz, 3H), 7.50 – 7.46 (m, 1H), 7.35 (d, *J* = 7.3 Hz, 2H), 7.30 – 7.26 (m, 6H), 7.08 (t, *J* = 7.1 Hz, 1H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.4, 164.9, 146.2, 140.6, 134.9, 134.8, 133.6, 133.3, 132.2, 132.0, 130.4, 130.0, 129.0, 128.5, 128.1, 127.5, 127.4, 126.8, 126.5, 126.2, 124.1, 122.7, 121.2, 119.2, 21.7; IR (neat): 3304 (br), 2920, 1682, 1628, 1584, 1507, 1445, 1383, 1308, 1264, 1189, 1067, 1009, 758, 669; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₁H₂₄BrN₂O₄S 599.0635, found 599.0634.

4-methyl-*N*-(2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**3s**)




3s

The reaction was conducted with 4-methyl-*N*-(2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1s**, 0.2 mmol, 103.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3s** (90.5 mg, 85%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 11.82 (s, 1H), 8.81 (d, *J* = 8.4 Hz, 1H), 7.88 – 7.82 (m, 4H), 7.77 (d, *J* = 7.9 Hz, 1H), 7.58 (t, *J* = 7.9 Hz, 1H), 7.47 (d, *J* = 2.2 Hz, 1H), 7.35 (d, *J* = 8.2 Hz, 2H), 7.30 – 7.23 (m, 8H), 7.04 (t, *J* = 7.6 Hz, 1H), 2.43 (s, 3H), 2.38 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 194.3, 166.0, 146.1, 142.5, 140.9, 134.9, 134.8, 133.5, 132.2, 131.7, 130.4, 130.0, 129.4, 128.5, 128.1, 127.5(0), 127.4(7), 127.4, 126.7, 126.1, 124.1, 122.3, 121.2, 119.1, 21.7, 21.5; IR (neat): 3284 (br), 2923, 1731, 1679, 1628, 1581,

1506, 1446, 1377, 1266, 1124, 1067, 1019, 967, 670; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{32}H_{27}N_2O_4S$ 535.1686, found 535.1684.

4-methoxy-*N*-(2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3t)




3t

The reaction was conducted with 4-methoxy-*N*-(2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1t**, 0.2 mmol, 107.0 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and $Cu(CH_3CN)_4BF_4$ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3t** (78.2 mg, 71%) as a pale yellow oil.

1H NMR (400 MHz, $CDCl_3$) δ 11.81 (s, 1H), 8.80 (d, $J = 8.5$ Hz, 1H), 7.95 (d, $J = 8.8$ Hz, 2H), 7.83 (d, $J = 8.2$ Hz, 2H), 7.77 (d, $J = 7.9$ Hz, 1H), 7.58 (t, $J = 7.9$ Hz, 1H), 7.49 – 7.46 (m, 1H), 7.35 (d, $J = 8.1$ Hz, 2H), 7.30 – 7.26 (m, 6H), 7.03 (t, $J = 7.6$ Hz, 1H), 6.94 (d, $J = 8.8$ Hz, 2H), 3.84 (s, 3H), 2.43 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 194.4, 165.5, 162.6, 146.1, 141.0, 134.9, 134.8, 133.6, 132.2, 130.4, 130.0, 129.4, 128.5, 128.1, 127.5, 127.4, 126.8, 126.7, 126.1, 124.0, 122.1, 121.1, 119.1, 113.9, 55.4, 21.7.; IR (neat): 3286 (br), 2925, 1729, 1677, 1626, 1581, 1507, 1446, 1375, 1253, 1114, 1067, 1028, 906, 669; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{32}H_{27}N_2O_5S$ 551.1635, found 551.1633.

***N*-(2-(4-phenyl-1-tosyl-1*H*-pyrrole-3-carbonyl)phenyl)acetamide (3u)**




3u

The reaction was conducted with *N*-(2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)acetamide (**1u**, 0.2 mmol, 88.6 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3u** (72.3 mg, 78%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 10.76 (s, 1H), 8.57 (d, *J* = 8.4 Hz, 1H), 7.83 (d, *J* = 8.4 Hz, 2H), 7.75 (d, *J* = 7.9 Hz, 1H), 7.55 (t, *J* = 7.3 Hz, 1H), 7.43 (d, *J* = 2.3 Hz, 1H), 7.36 (d, *J* = 8.3 Hz, 2H), 7.31 – 7.26 (m, 6H), 7.06 (t, *J* = 7.6 Hz, 1H), 2.45 (s, 3H), 2.13 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 193.6, 169.2, 146.2, 140.2, 134.9, 134.5, 133.0, 132.2, 130.4, 130.2, 128.5, 128.2, 127.6, 127.4, 126.8, 126.4, 124.2, 122.3, 121.3, 119.3, 25.3, 21.7; IR (neat): 3370 (br), 2924, 1696, 1631, 1596, 1581, 1517, 1448, 1374, 1266, 1173, 1067, 1008, 967, 669; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₆H₂₃N₂O₄S 459.1373, found 459.1370.

(2-(methylamino)phenyl)(4-phenyl-1-tosyl-1*H*-pyrrol-3-yl)methanone (3v)




3v

The reaction was conducted with 4-methyl-*N*-(3-(2-(methylamino)phenyl)prop-2-yn-1-yl)-*N*-(phenylethynyl)benzenesulfonamide (**1v**, 0.2 mmol, 88.6 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.3 mmol, 49.2 mg), and Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3v** (60.6 mg, 70%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.54 (s, 1H), 7.81 (d, *J* = 8.2 Hz, 2H), 7.67 (d, *J* = 7.9 Hz, 1H), 7.40 – 7.32 (m, 4H), 7.27 – 7.20 (m, 6H), 6.69 (d, *J* = 8.5 Hz, 1H), 6.51 (t, *J* = 7.5 Hz, 1H), 2.88 (d, *J* = 5.0 Hz, 3H), 2.43 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 193.0,

152.5, 145.8, 135.3, 134.8, 132.7, 130.3, 130.0, 128.4, 127.9, 127.2, 123.9, 118.4, 118.3, 113.8, 110.9, 29.3, 21.7; IR (neat): 3370 (br), 2924, 1696, 1631, 1596, 1581, 1517, 1448, 1374, 1266, 1173, 1067, 1008, 967, 669; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{26}H_{23}N_2O_4S$ 459.1373, found 459.1370.

***N*-(3-(5-oxo-4-phenyl-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (3wa)**




3wa

The reaction was conducted with *N*-(3-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl)benzamide (**1w**, 0.2 mmol, 101.0 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.6 mmol, 98.4 mg), $Cu(CH_3CN)_4BF_4$ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 4:1) yielded **3wa** (71.0 mg, 66%) as a pale yellow oil.

1H NMR (400 MHz, $CDCl_3$) δ 8.06 – 8.02 (m, 2H), 7.90 (d, $J = 8.2$ Hz, 2H), 7.79 (s, 1H), 7.71 (d, $J = 7.6$ Hz, 2H), 7.45 – 7.30 (m, 4H), 7.24 – 7.19 (m, 5H), 7.14 – 7.03 (m, 3H), 4.76 (s, 2H), 2.33 (s, 3H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 192.1, 166.8, 165.7, 147.9, 145.7, 138.8, 136.5, 135.0, 134.7, 134.2, 132.1, 129.9, 129.8, 129.6, 129.2, 128.8, 128.6, 128.3(4), 128.2(8), 127.0, 125.8, 125.1, 120.6, 50.8, 21.7; IR (neat): 3358 (br), 2922, 1725, 1653, 1592, 1539, 1483, 1431, 1362, 1327, 1259, 1171, 1089, 668, 583; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{31}H_{25}N_2O_5S$ 537.1479, found 537.1475.

2-(5-oxo-4-phenyl-1-tosyl-2,5-dihydro-1*H*-pyrrole-3-carbonyl)phenyl benzoate (3xa)




3xa

The reaction was conducted with 2-(3-((4-methyl-*N*-(phenylethynyl)phenyl)sulfonamido)prop-1-yn-1-yl)phenyl benzoate (**1x**, 0.2 mmol, 101.2 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.6 mmol, 98.4 mg), Cu(CH₃CN)₄BF₄ (0.02 mmol, 6.3 mg) in DCE (4.0 mL) at 80 °C (80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 4:1) yielded **3xa** (82.8 mg, 77%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.11 (d, *J* = 8.0 Hz, 2H), 7.94 (d, *J* = 8.0 Hz, 2H), 7.68 (t, *J* = 7.0 Hz, 1H), 7.55 – 7.52 (m, 3H), 7.44 (t, *J* = 7.8 Hz, 1H), 7.31 (d, *J* = 8.0 Hz, 2H), 7.26 – 7.23 (m, 2H), 7.19 – 7.06 (m, 5H), 4.69 (s, 2H), 2.42 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 190.1, 166.6, 164.8, 149.4, 147.1, 145.5, 137.9, 134.8, 134.4, 134.3, 131.0, 130.0, 129.8, 129.7, 129.6, 129.0, 128.9, 128.5, 128.2, 128.1, 128.0, 125.9, 123.4, 50.2, 21.7; IR (neat): 2920, 1730, 1653, 1600, 1492, 1448, 1368, 1327, 1261, 1189, 1172, 1089, 1058, 964, 668; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₁H₂₄NO₆S 538.1319, found 538.1318.


4-benzoyl-3-phenyl-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (**3ya**)



3ya

The reaction was conducted with 4-methyl-*N*-(phenylethynyl)-*N*-(3-phenylprop-2-yn-1-yl)benzenesulfonamide (**1y**, 0.2 mmol, 77.0 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.6 mmol, 98.4 mg), and Cu(CH₃CN)₄PF₆ (0.02 mmol, 7.5 mg) in DCE (4.0 mL) at 80 °C


(80 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 5:1) yielded **3ya** (60.3 mg, 72%) as a pale yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 8.04 (d, *J* = 7.6 Hz, 2H), 7.67 (d, *J* = 7.3 Hz, 2H), 7.46 (t, *J* = 6.8 Hz, 1H), 7.37 (d, *J* = 7.6 Hz, 2H), 7.29 – 7.26 (m, 4H), 7.21 – 7.13 (m, 3H), 4.80 (s, 2H), 2.44 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 192.5, 166.6, 147.6, 145.6, 136.4, 134.8, 134.4, 134.2, 129.9, 129.7, 129.4, 129.2, 128.7, 128.6, 128.4, 128.3, 50.6, 21.7; IR (neat): 2923, 1724, 1653, 1596, 1493, 1448, 1365, 1328, 1254, 1188, 1172, 1115, 1090, 963, 667; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₄H₂₀NO₄S 418.1108, found 418.1106.



General procedure for the synthesis of dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-ones **5**:

3,5-Dichloropyridine *N*-oxide **2a** (0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) were added in this order to the diynes **4** (0.2 mmol) in PhCF₃ (4.0 mL) at room temperature. The reaction mixture was stirred at 60 °C (60 °C, heating mantle temperature) and the progress of the reaction was monitored by TLC. The reaction typically took 1 h. Upon completion, the mixture was then concentrated and the residue was purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired products **5**.


8-methyl-2-tosyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (**5a**)



5a

The reaction was conducted with *N*-(but-2-yn-1-yl)-4-methyl-*N*-(phenylethynyl)benzenesulfonamide (**4a**, 0.2 mmol, 64.6 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5a** (48.8 mg, 72%) as a yellow solid (mp 174-176 °C). ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, *J* = 7.2 Hz, 2H), 7.62 (d, *J* = 6.7 Hz, 1H), 7.42 (d, *J* = 6.3 Hz, 1H), 7.34 (d, *J* = 7.7 Hz, 2H), 7.29 – 7.28 (m, 2H), 4.73 (s, 2H), 3.74 (q, *J* = 7.2 Hz, 1H), 2.42 (s, 3H), 1.43 (d, *J* = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.5, 163.5, 151.2, 145.0, 139.0, 135.6, 134.3, 129.7, 128.0, 127.3, 126.7, 123.5, 120.9, 49.4, 42.3, 21.6, 15.5; IR (neat): 2922, 1724, 1597, 1362, 1307, 1169, 1132, 1090, 672, 580, 545; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₉H₁₈NO₃S 340.1002, found 340.1001.

8-methyl-2-(phenylsulfonyl)-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (**5b**)




5b

The reaction was conducted with *N*-(but-2-yn-1-yl)-*N*-(phenylethynyl)benzenesulfonamide (**4b**, 0.2 mmol, 61.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5b** (54.0 mg, 83%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, *J* = 7.3 Hz, 2H), 7.66 – 7.61 (m, 2H), 7.57 – 7.54 (m, 2H), 7.42 (d, *J* = 6.2 Hz, 1H), 7.31 – 7.26 (m, 2H), 4.74 (s, 2H), 3.75 (q, *J* = 7.2 Hz, 1H), 1.43 (d, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.7, 163.5, 151.2, 138.9, 138.5, 134.2, 133.9, 129.1, 127.9, 127.3, 126.7, 123.5, 120.9, 49.5, 42.3, 15.4; IR (neat): 2930, 1738, 1448, 1360, 1307, 1171, 1134, 1090, 775, 608, 569; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₈H₁₆NO₃S 326.0845, found 326.0844.

2-((4-methoxyphenyl)sulfonyl)-8-methyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (5c)




5c

The reaction was conducted with *N*-(but-2-yn-1-yl)-4-methoxy-*N*-(phenylethynyl)benzenesulfonamide (**4c**, 0.2 mmol, 67.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5c** (62.5 mg, 88%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, *J* = 7.2 Hz, 2H), 7.62 (d, *J* = 6.8 Hz, 1H), 7.42 (d, *J* = 6.7 Hz, 1H), 7.32 – 7.27 (m, 2H), 7.01 (d, *J* = 7.2 Hz, 2H), 4.73 (s, 2H), 3.86 (s, 3H), 3.75 (q, *J* = 7.1 Hz, 1H), 1.44 (d, *J* = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 163.9, 163.6, 151.2, 139.1, 134.4, 130.4, 130.1, 127.4, 126.7, 123.5, 120.9, 114.3, 55.7, 49.4, 42.3, 15.5; IR (neat): 2930, 1721, 1595, 1498, 1359, 1263, 1164, 1091, 675, 580, 554; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₉H₁₈NO₄S 356.0951, found 356.0950.

2-((4-bromophenyl)sulfonyl)-8-methyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (5d)




5d

The reaction was conducted with 4-bromo-*N*-(but-2-yn-1-yl)-*N*-(phenylethynyl)benzenesulfonamide (**4d**, 0.2 mmol, 77.6 mg), 3,5-dichloropyridine *N*-

oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5d** (56.6 mg, 70%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 7.2 Hz, 2H), 7.61 (d, *J* = 7.2 Hz, 2H), 7.54 (d, *J* = 6.8 Hz, 1H), 7.35 (d, *J* = 6.8 Hz, 1H), 7.25 – 7.21 (m, 2H), 4.65 (s, 2H), 3.68 (q, *J* = 7.7 Hz, 1H), 1.36 (d, *J* = 7.5 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.8, 163.5, 151.1, 138.9, 137.5, 134.1, 132.4, 129.5, 129.3, 127.4, 126.8, 123.6, 120.9, 49.5, 42.4, 15.5; IR (neat): 2930, 1736, 1574, 1471, 1364, 1172, 1133, 1068, 744, 616, 572; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₈H₁₅BrNO₃S 403.9951, found 403.9950.

6-fluoro-8-methyl-2-tosyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (**5e**)




5e

The reaction was conducted with *N*-(but-2-yn-1-yl)-*N*-((4-fluorophenyl)ethynyl)-4-methylbenzenesulfonamide (**4e**, 0.2 mmol, 68.2 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5e** (36.4 mg, 51%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 8.2 Hz, 2H), 7.51 – 7.43 (m, 1H), 7.27 (d, *J* = 7.4 Hz, 2H), 7.06 (d, *J* = 8.6 Hz, 1H), 6.93 (t, *J* = 8.5 Hz, 1H), 4.64 (s, 2H), 3.67 (q, *J* = 7.1 Hz, 1H), 2.35 (s, 3H), 1.36 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.7, 163.4 (d, *J* = 20.0 Hz), 161.0, 153.5 (d, *J* = 8.0 Hz), 145.1, 138.4, 135.6, 130.4 (d, *J* = 2.0 Hz), 129.8, 128.1, 121.8 (d, *J* = 9.0 Hz), 114.3 (d, *J* = 23.0 Hz), 111.7 (d, *J* = 24.0 Hz), 49.3, 42.4, 21.7, 15.5; IR (neat): 2922, 1724, 1598, 1509, 1360, 1307, 1162, 1091, 814, 665, 546; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₉H₁₇FNO₃S 358.0908, found 358.0907.

6-chloro-8-methyl-2-tosyl-1,8-dihydroindeno[1,2-c]pyrrol-3(2H)-one (5f)




5f

The reaction was conducted with *N*-(but-2-yn-1-yl)-*N*-((4-chlorophenyl)ethynyl)-4-methylbenzenesulfonamide (**4f**, 0.2 mmol, 71.6 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5f** (34.4 mg, 46%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, *J* = 7.1 Hz, 2H), 7.53 (d, *J* = 7.5 Hz, 1H), 7.40 – 7.35 (m, 3H), 7.30 – 7.27 (m, 1H), 4.73 (s, 2H), 3.75 (q, *J* = 7.4 Hz, 1H), 2.43 (s, 3H), 1.44 (d, *J* = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 163.2, 152.8, 145.2, 138.5, 135.5, 132.8 (9), 132.8 (6), 129.8, 128.1, 127.7, 124.3, 121.7, 49.3, 42.4, 21.7, 15.4; IR (neat): 2927, 1731, 1597, 1440, 1362, 1303, 1170, 1091, 662, 588, 545; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₉H₁₇ClNO₃S 374.0612, found 374.0611.

6-bromo-8-methyl-2-tosyl-1,8-dihydroindeno[1,2-c]pyrrol-3(2H)-one (5g)




5g

The reaction was conducted with *N*-((4-bromophenyl)ethynyl)-*N*-(but-2-yn-1-yl)-4-methylbenzenesulfonamide (**4g**, 0.2 mmol, 80.4 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle

temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5g** (39.3 mg, 47%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 8.4 Hz, 2H), 7.48 (s, 1H), 7.42 – 7.35 (m, 2H), 7.28 (d, *J* = 8.1 Hz, 2H), 4.64 (s, 2H), 3.67 (q, *J* = 15.2, 7.6 Hz, 1H), 2.36 (s, 3H), 1.36 (d, *J* = 7.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 169.4, 163.1, 153.1, 145.2, 138.5, 135.5, 133.3, 130.6, 129.8, 128.1, 127.1, 122.1, 120.9, 49.3, 42.4, 21.7, 15.3; IR (neat): 2925, 1729, 1596, 1462, 1362, 1302, 1169, 1090, 674, 586, 545; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₉H₁₇BrNO₃S 418.0107, found 418.0105.

8-methyl-2-tosyl-6-(trifluoromethyl)-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (**5h**)




5h

The reaction was conducted with *N*-(but-2-yn-1-yl)-4-methyl-*N*-((4-(trifluoromethyl)phenyl)ethynyl)benzenesulfonamide (**4h**, 0.2 mmol, 78.2 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5h** (59.4 mg, 73%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, *J* = 8.3 Hz, 2H), 7.64 (d, *J* = 7.8 Hz, 1H), 7.58 (s, 1H), 7.51 (d, *J* = 8.0 Hz, 1H), 7.29 (d, *J* = 8.1 Hz, 2H), 4.70 (s, 2H), 3.76 (q, *J* = 7.6 Hz, 1H), 2.36 (s, 3H), 1.40 (d, *J* = 7.7 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.6, 162.9, 151.5, 145.3, 138.5, 137.7, 135.5, 129.8, 128.1, 125.0 (q, *J* = 3.8 Hz), 121.1, 120.5, 120.4, 49.5, 42.6, 21.7, 15.2; IR (neat): 2925, 1734, 1597, 1433, 1361, 1326, 1170, 1090, 672, 610, 577; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₀H₁₇F₃NO₃S 408.0876, found 408.0875.

5,7-dichloro-8-methyl-2-tosyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (**5i**)




5i

The reaction was conducted with *N*-(but-2-yn-1-yl)-*N*-((3,5-dichlorophenyl)ethynyl)-4-methylbenzenesulfonamide (**4i**, 0.2 mmol, 78.4 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5i** (54.7 mg, 67%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.94 (d, *J* = 7.3 Hz, 2H), 7.45 (s, 1H), 7.28 (d, *J* = 7.8 Hz, 2H), 7.16 (s, 1H), 4.67 (s, 2H), 3.82 (q, *J* = 7.3 Hz, 1H), 2.36 (s, 3H), 1.45 (d, *J* = 7.5 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.3, 162.6, 145.8, 145.3, 137.5, 137.3, 135.3, 134.5, 130.7, 129.8, 128.1, 127.0, 120.0, 49.3, 42.7, 21.7, 13.7; IR (neat): 2921, 1727, 1595, 1422, 1361, 1298, 1170, 1095, 837, 600, 543; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₁₉H₁₆Cl₂NO₃S 408.0222, found 408.0223.

6,8-dimethyl-2-tosyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (**5j**)




5j

The reaction was conducted with *N*-(but-2-yn-1-yl)-4-methyl-*N*-(*p*-tolylethynyl)benzenesulfonamide (**4j**, 0.2 mmol, 67.4 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 4:1) yielded **5j** (57.2 mg, 81%) as a pale yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 8.01 (d, $J = 7.5$ Hz, 2H), 7.49 (d, $J = 7.6$ Hz, 1H), 7.34 (d, $J = 7.6$ Hz, 2H), 7.23 (s, 1H), 7.10 (d, $J = 7.6$ Hz, 1H), 4.70 (s, 2H), 3.70 (q, $J = 7.4$ Hz, 1H), 2.42 (s, 3H), 2.39 (s, 3H), 1.41 (d, $J = 7.6$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.7, 163.6, 151.5, 144.9, 138.9, 136.7, 135.7, 131.6, 129.7, 128.0, 124.4, 120.5, 49.4, 42.1, 21.6 (3), 21.6 (0), 15.6; IR (neat): 2921, 1731, 1597, 1441, 1359, 1304, 1171, 1090, 820, 674, 584; HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_3\text{S}$ 354.1158, found 354.1156.

5,7,8-trimethyl-2-tosyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (5k)




5k

The reaction was conducted with *N*-(but-2-yn-1-yl)-*N*-((3,5-dimethylphenyl)ethynyl)-4-methylbenzenesulfonamide (**4k**, 0.2 mmol, 70.2 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh_3AuCl (0.01 mmol, 5.0 mg), AgNTf_2 (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF_3 (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5k** (52.1 mg, 71%) as a pale yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 8.01 (d, $J = 7.7$ Hz, 2H), 7.35 – 7.29 (m, 3H), 6.87 (s, 1H), 4.70 (s, 2H), 3.75 (q, $J = 7.2$ Hz, 1H), 2.42 (s, 3H), 2.37 (s, 3H), 2.31 (s, 3H), 1.41 (d, $J = 7.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.8, 163.8, 146.1, 144.9, 138.6, 137.5, 135.7, 134.4, 133.5, 129.7, 129.3, 128.0, 119.3, 49.3, 41.6, 21.6, 21.1, 18.6, 14.7; IR (neat): 2923, 1730, 1597, 1443, 1360, 1170, 1123, 1089, 851, 665, 545; HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{21}\text{H}_{22}\text{NO}_3\text{S}$ 368.1315, found 368.1316.

8-ethyl-2-tosyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (5l)




5l

The reaction was conducted with 4-methyl-*N*-(pent-2-yn-1-yl)-*N*-(phenylethynyl)benzenesulfonamide (**4l**, 0.2 mmol, 107.8 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5l** (56.5 mg, 80%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 7.6 Hz, 2H), 7.61 (d, *J* = 6.7 Hz, 1H), 7.41 (d, *J* = 6.4 Hz, 1H), 7.34 (d, *J* = 7.8 Hz, 2H), 7.29 – 7.22 (m, 2H), 4.76 (d, *J* = 5.5 Hz, 2H), 3.69 (t, *J* = 10.8 Hz, 1H), 2.42 (s, 3H), 2.09 – 2.00 (m, 1H), 1.83 – 1.74 (m, 1H), 0.90 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 168.2, 163.5, 149.4, 145.0, 139.9, 135.6, 134.9, 129.8, 128.0, 127.4, 126.6, 123.8, 120.9, 50.2, 49.3, 23.7, 21.7, 11.1; IR (neat): 2931, 1728, 1597, 1458, 1360, 1170, 1133, 1091, 776, 671, 544; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₀H₂₀NO₃S 354.1158, found 354.1159.

8-ethyl-2-((4-methoxyphenyl)sulfonyl)-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (5m)




5m

The reaction was conducted with 4-methoxy-*N*-(pent-2-yn-1-yl)-*N*-(phenylethynyl)benzenesulfonamide (**4m**, 0.2 mmol, 70.6 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating

mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5m** (53.2 mg, 72%) as a pale yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 8.08 (d, $J = 7.7$ Hz, 2H), 7.62 (d, $J = 7.3$ Hz, 1H), 7.42 (d, $J = 6.9$ Hz, 1H), 7.32 – 7.27 (m, 2H), 7.01 (d, $J = 7.8$ Hz, 2H), 4.81 – 4.70 (m, 2H), 3.86 (s, 3H), 3.69 (t, 1H), 2.10 – 2.03 (m, 1H), 1.84 – 1.77 (m, 1H), 0.91 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.1, 163.9, 163.5, 149.5, 139.9, 134.9, 130.3, 130.0, 127.3, 126.6, 123.8, 120.9, 114.3, 55.7, 50.1, 49.3, 23.7, 11.1; IR (neat): 2923, 1729, 1595, 1458, 1361, 1164, 1134, 1090, 835, 675, 587; HRMS (ESI) m/z : $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_4\text{S}$ 370.1108, found 370.1107.

8-pentyl-2-tosyl-1,8-dihydroindeno[1,2-c]pyrrol-3(2H)-one (**5n**)




5n

The reaction was conducted with 4-methyl-*N*-(oct-2-yn-1-yl)-*N*-(phenylethynyl)benzenesulfonamide (**4n**, 0.2 mmol, 76.0 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh_3AuCl (0.01 mmol, 5.0 mg), AgNTf_2 (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF_3 (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5n** (58.6 mg, 74%) as a pale yellow oil.

^1H NMR (400 MHz, CDCl_3) δ 8.02 (d, $J = 7.5$ Hz, 2H), 7.62 (d, $J = 7.0$ Hz, 1H), 7.41 (d, $J = 6.9$ Hz, 1H), 7.35 (d, $J = 7.8$ Hz, 2H), 7.29 – 7.26 (m, 2H), 4.81 – 4.70 (m, 2H), 3.73 – 3.70 (m, 1H), 2.43 (s, 3H), 2.01 – 1.94 (m, 1H), 1.74 – 1.68 (m, 1H), 1.31 (s, 6H), 0.94 – 0.83 (m, 3H); ^{13}C NMR (100 MHz, CDCl_3) δ 168.5, 163.5, 149.8, 145.0, 139.7, 135.6, 134.7, 129.8, 128.0, 127.3, 126.6, 123.8, 120.9, 50.2, 48.1, 31.8, 30.6, 26.6, 22.4, 21.7, 14.0; IR (neat): 2927, 1730, 1597, 1457, 1360, 1170,

1133, 1089, 777, 671, 544; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{23}H_{26}NO_3S$ 396.1628, found 396.1629.

8-(3-phenylpropyl)-2-tosyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (5o)




5o

The reaction was conducted with 4-methyl-*N*-(phenylethynyl)-*N*-(6-phenylhex-2-yn-1-yl)benzenesulfonamide (**4o**, 0.2 mmol, 85.6 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh_3AuCl (0.01 mmol, 5.0 mg), $AgNTf_2$ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in $PhCF_3$ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5o** (46.2 mg, 52%) as a pale yellow oil.

1H NMR (400 MHz, $CDCl_3$) δ 7.92 (d, $J = 6.5$ Hz, 2H), 7.53 (d, $J = 7.2$ Hz, 1H), 7.30 – 7.13 (m, 8H), 7.05 (d, $J = 6.3$ Hz, 2H), 4.60 (s, 2H), 3.67 – 3.59 (m, 1H), 2.55 (t, $J = 6.5$ Hz, 2H), 2.34 (s, 3H), 1.96 – 1.88 (m, 1H), 1.73 – 1.65 (m, 1H), 1.61 – 1.48 (m, 2H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 168.1, 163.4, 149.5, 145.0, 141.3, 139.8, 135.6, 134.7, 129.7, 128.5, 128.3, 128.0, 127.4, 126.6, 126.1, 123.8, 121.0, 50.1, 47.9, 35.7, 29.9, 28.4, 21.6; IR (neat): 2923, 1729, 1598, 1456, 1360, 1170, 1131, 1090, 777, 672, 588; HRMS (ESI) m/z : $[M + H]^+$ calcd for $C_{27}H_{26}NO_3S$ 444.1628, found 444.1627.

4-methyl-2-tosyl-2,3,4,5-tetrahydro-1H-benzo[*e*]isoindol-1-one (5pa)




5pa

The reaction was conducted with *N*-(but-2-yn-1-yl)-4-methyl-*N*-(otolylethynyl) benzenesulfonamide (**4p**, 0.2 mmol, 67.4 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5pa** (35.4 mg, 50%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 8.09 – 8.00 (m, 3H), 7.34 (d, *J* = 6.0 Hz, 2H), 7.20 – 7.14 (m, 3H), 4.57 – 4.41 (m, 2H), 3.01 – 2.87 (m, 2H), 2.71 – 2.65 (m, 1H), 2.43 (s, 3H), 1.25 – 1.19 (m, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 166.8, 158.7, 145.0, 135.6, 134.1, 129.7, 128.6, 128.1, 127.9, 127.4, 127.2, 127.0, 123.7, 50.1, 36.0, 29.4, 21.7, 17.2; IR (neat): 2926, 1721, 1597, 1453, 1362, 1170, 1114, 1090, 783, 671, 587; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₀H₂₀NO₃S 354.1158, found 354.1160.

3-(2,6-dimethylphenyl)-4-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-tosyl-1,5-dihydro-2*H*-pyrrol-2-one (**5qa**)



5qa


The reaction was conducted with *N*-((2,6-dimethylphenyl)ethynyl)-4-methyl-*N*-(6-phenylhex-2-yn-1-yl)benzenesulfonamide (**4q**, 0.2 mmol, 91.2 mg), 3,5-dichloropyridine *N*-oxide (**2a**, 0.24 mmol, 39.4 mg), PPh₃AuCl (0.01 mmol, 5.0 mg), AgNTf₂ (0.01 mmol, 3.9 mg), and NaBARF (0.02 mmol, 17.7 mg) in PhCF₃ (4.0 mL) at 60 °C (60 °C, heating mantle temperature). Purification by column chromatography on silica gel (petroleum ether/ethyl acetate = 10:1) yielded **5qa** (59.6 mg, 65%) as a pale yellow oil.

¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, *J* = 8.3 Hz, 2H), 7.33 – 7.29 (m, 4H), 7.19 – 7.10 (m, 3H), 7.04 – 6.99 (m, 2H), 5.85 – 5.77 (m, 1H), 4.63 (s, 2H), 2.80 – 2.77 (m, 2H), 2.62 – 2.57 (m, 2H), 2.43 (s, 3H), 2.07 – 1.99 (m, 2H), 1.91 (s, 6H), 0.96 – 0.83 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 167.3, 150.2, 145.0, 140.3, 139.7, 137.1, 135.5, 133.9, 129.6,

128.8, 128.6, 128.0, 127.4, 126.4, 121.0, 51.8, 35.3, 32.0, 21.7, 20.0; IR (neat): 2923, 1721, 1596, 1454, 1362, 1171, 1031, 1052, 775, 655, 585; HRMS (ESI) m/z: [M + H]⁺ calcd for C₂₉H₃₀NO₃S 472.1941, found 472.1944.


Synthetic Applications

N-(2-(4-phenyl-1*H*-pyrrole-3-carbonyl)phenyl)benzamide (**6**)



KOH (1.0 mmol, 56.0 mg) was added to a solution of compound **3a** (0.2 mmol, 73.2 mg) in MeOH/THF (2.0 ml/2.0 ml) at room temperature. The reaction mixture was stirred at 80 °C (80 °C, heating mantle temperature) and the progress of the reaction was monitored by TLC. Upon completion, the mixture was then concentrated and the residue was purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired product **6** (60.0 mg, 82% yield, yellow oil). ¹H NMR (400 MHz, CDCl₃) δ 11.74 (s, 1H), 8.91 (s, 1H), 8.71 (d, *J* = 6.7 Hz, 1H), 7.98 (d, *J* = 6.0 Hz, 2H), 7.80 (d, *J* = 6.9 Hz, 1H), 7.56 – 7.43 (m, 4H), 7.37 – 7.23 (m, 5H), 7.05 – 6.99 (m, 2H), 6.91 – 6.87 (m, 1H); ¹³C NMR (100 MHz, CDCl₃) δ 194.5, 166.2, 139.7, 134.4, 134.3, 133.4, 133.2, 132.0, 128.7, 128.3(2), 128.2(5), 127.5, 127.1, 126.9, 126.5, 126.3, 122.7, 122.4, 121.5, 118.8; IR (neat): 3278 (br), 2920, 1661, 1600, 1580, 1510, 1492, 1448, 1436, 1383, 1307, 1293, 756, 696; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₄H₁₉N₂O₂ 367.1441, found 367.1440.


(2-(benzylamino)phenyl)(4-phenyl-1-tosyl-1*H*-pyrrol-3-yl)methanol (**7**)



To a mixture of I₂ (0.04 mmol, 10.2 mg), and NaBH₄ (1.0 mmol, 38.0 mg) was added to a solution of the compound **3a** (0.2 mmol, 73.2 mg) in dry THF (4.0 mL) at room


temperature. The reaction mixture was stirred at room temperature and the progress of the reaction was monitored by TLC. Upon completion, the mixture was then concentrated and the residue was purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired product **7** (84.5 mg, 83% yield, yellow oil). ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 8.1 Hz, 2H), 7.30 – 7.10 (m, 17H), 6.97 (d, *J* = 7.3 Hz, 1H), 6.60 (d, *J* = 7.9 Hz, 2H), 5.84 (s, 1H), 4.25 (s, 2H), 2.37 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 145.9, 145.2, 139.3, 135.8, 133.2, 130.0, 129.2, 129.1, 128.5, 128.3, 127.6, 127.3, 127.0(4), 126.9(9), 126.0, 120.0, 118.6, 116.8, 111.6, 68.2, 47.7, 21.6; IR (neat): 3527 (br), 3405 (br), 2923, 1603, 1584, 1518, 1452, 1371, 1318, 1188, 1172, 1090, 1067, 966, 671; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₃₁H₂₉N₂O₃S 509.1893, found 509.1892.

***N*-((1-ethyl-3-(hydroxymethyl)-1*H*-inden-2-yl)methyl)-4-methylbenzenesulfonamide (8)**



DIBAL-H (0.6 mmol, 0.6 mL, 1.0 M) was added dropwise to a solution of compound **5I** (0.2 mmol, 71.4 mg) in dry DCM (4.0 mL) at -78 °C. The reaction mixture was stirred at -78 °C and the progress of the reaction was monitored by TLC. Upon completion, the mixture was then concentrated and the residue was purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired product **8** (70.7 mg, 99% yield, yellow oil). ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 8.3 Hz, 2H), 7.35 – 7.31 (m, 2H), 7.26 – 7.17 (m, 4H), 5.32 – 5.27 (m, 1H), 4.63 – 4.54 (m, 2H), 4.10 – 4.06 (m, 1H), 3.81 – 3.75 (m, 1H), 3.33 (t, *J* = 5.0 Hz, 1H), 2.39 (s, 3H), 2.01 – 1.95 (m, 1H), 1.74 – 1.67 (m, 2H), 0.50 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 146.3, 143.5, 143.3, 142.0, 140.0, 136.7, 129.7, 127.1, 126.5, 125.4, 123.0, 119.4, 56.3, 50.5, 39.0, 22.2, 21.5, 8.7; IR (neat): 3480 (br), 3276 (br), 2927, 1721, 1598, 1459, 1324, 1289, 1158, 1093, 814, 661, 550; HRMS (ESI) *m/z*: [M + Na]⁺ calcd for C₂₀H₂₃NNaO₃S 380.1291, found 380.1292.

methyl 1-ethyl-2-(((4-methylphenyl)sulfonamido)methyl)-1H-indene-3-carboxylate (9)



TsNHNH₂ (0.4 mmol, 74.4 mg) was added dropwise to a solution of compound **5I** (0.2 mmol, 71.4 mg) in MeOH (4.0 mL) at room temperature. The reaction mixture was stirred at 80 °C and the progress of the reaction was monitored by TLC. Upon completion, the mixture was then concentrated and the residue was purified by chromatography on silica gel (eluent: petroleum ether/ethyl acetate) to afford the desired product **9** (45.4 mg, 59% yield) as a yellow solid (mp 141-143 °C). ¹H NMR (400 MHz, CDCl₃) δ 7.75 (d, *J* = 7.8 Hz, 2H), 7.49 (d, *J* = 7.4 Hz, 1H), 7.34 – 7.26 (m, 4H), 7.20 (t, *J* = 7.3 Hz, 1H), 5.12 – 5.09 (m, 1H), 4.22 (s, 1H), 4.08 – 4.03 (m, 1H), 3.96 – 3.89 (m, 1H), 3.70 (s, 3H), 2.52 (q, *J* = 7.6 Hz, 2H), 2.40 (s, 3H), 1.14 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ 171.4, 146.6, 144.2, 143.4, 140.1, 136.8, 132.5, 129.6, 127.7, 127.2, 125.8, 123.9, 119.7, 55.4, 52.6, 39.9, 21.5, 18.6, 13.4; IR (neat): 3285 (br), 2922, 1731, 1598, 1434, 1326, 1160, 1092, 1062, 814, 734, 662; HRMS (ESI) *m/z*: [M + H]⁺ calcd for C₂₁H₂₄NO₄S 386.1421, found 386.1422.

Reference

- (1) G. Evindar, R. A. Batey, *J. Org. Chem.* 2006, **71**, 1802-1808.
- (2) W.-B. Shen, X.-T. Tang, T.-T. Zhang, S.-Y. Liu, J.-M. He, T.-F. Su, *Org. Lett.* 2020, **22**, 6799-6804.
- (3) E. Benedetti, A. Simonneau, A. Hours, H. Amouri, A. Penoni, G. Palmisano, M. Malacria, J.-P. Goddard, L. Fensterbank, *Adv. Synth. & Catal.* 2011, **353**, 1908-1912.

***N*-2-(1-(methylsulfonyl)-4-phenyl-1*H*-pyrrole-3-carbonyl)phenylbenzamide (3d).**

CCDC Number = 2049243

Crystal of **3d** was grown by slow evaporation of hexane/ethyl acetate solution of **3d** at room temperature (25 °C). X-ray diffraction data was collected at 293 K on a Rigaku Gemini E diffractometer with graded-multilayer focused CuK(alpha) X-rays.




Figure S1. Crystal structure of **3d** with thermal ellipsoids at 50% probability

Bond precision:	C-C = 0.0040 A	Wavelength=1.54184	
Cell:	a=8.9146 (9)	b=11.2178 (9)	c=11.8266 (7)
	alpha=79.648 (6)	beta=70.259 (8)	gamma=85.201 (7)
Temperature:	293 K		
	Calculated	Reported	
Volume	1094.72 (17)	1094.72 (16)	
Space group	P -1	P -1	
Hall group	-P 1	-P 1	
Moiety formula	C25 H20 N2 O4 S	C25 H20 N2 O4 S	
Sum formula	C25 H20 N2 O4 S	C25 H20 N2 O4 S	
Mr	444.49	444.49	
Dx, g cm-3	1.349	1.348	
Z	2	2	
Mu (mm-1)	1.606	1.606	
F000	464.0	464.0	
F000'	466.02		
h, k, lmax	10, 13, 14	10, 13, 14	
Nref	3917	3915	
Tmin, Tmax	0.825, 0.865	0.897, 1.000	
Tmin'	0.786		
Correction method= # Reported T Limits:	Tmin=0.897 Tmax=1.000		
AbsCorr = MULTI-SCAN			
Data completeness=	0.999	Theta(max)=	67.071
R(reflections)=	0.0473 (2885)	wR2(reflections)=	0.1299 (3915)
S =	1.008	Npar=	290

8-methyl-2-tosyl-1,8-dihydroindeno[1,2-*c*]pyrrol-3(2*H*)-one (5a). CCDC Number = 2086108

Crystal of **5a** was grown by slow evaporation of hexane/dichloromethane solution of **5a** at room temperature (25 °C). X-ray diffraction data was collected at 293 K on a Rigaku Gemini E diffractometer with graded-multilayer focused CuK(alpha) X-rays.




Figure S2. Crystal structure of **5a** with thermal ellipsoids at 50% probability

Bond precision:	C-C = 0.0053 Å	Wavelength=1.54184	
Cell:	a=6.0727 (4)	b=12.1141 (8)	c=12.8850 (7)
	alpha=86.689 (5)	beta=84.600 (5)	gamma=79.238 (6)
Temperature:	293 K		
	Calculated	Reported	
Volume	926.30 (10)	926.29 (10)	
Space group	P -1	P -1	
Hall group	-P 1	-P 1	
Moiety formula	C19 H17 N O3 S [+ solvent]	C19 H17 N O3 S	
Sum formula	C19 H17 N O3 S [+ solvent]	C19 H17 N O3 S	
Mr	339.40	339.39	
Dx, g cm ⁻³	1.217	1.217	
Z	2	2	
Mu (mm ⁻¹)	1.679	1.679	
F000	356.0	356.0	
F000'	357.67		
h, k, lmax	7, 14, 15	7, 14, 15	
Nref	3321	3305	
Tmin, Tmax	0.785, 0.845	0.908, 1.000	
Tmin'	0.764		
Correction method= #	Reported T Limits: Tmin=0.908 Tmax=1.000		
AbsCorr =	MULTI-SCAN		
Data completeness=	0.995	Theta(max) = 67.031	
R(reflections)=	0.0754 (2536)	wR2(reflections)= 0.2533 (3305)	
S =	1.056	Npar= 236	

methyl 1-ethyl-2-(((4-methylphenyl)sulfonamido)methyl)-1*H*-indene-3-carboxylate (9). CCDC Number = 2086109

Crystal of **9** was grown by slow evaporation of hexane/dichloromethane solution of **9** at room temperature (25 °C). X-ray diffraction data was collected at 293 K on a Rigaku Gemini E diffractometer with graded-multilayer focused CuK(alpha) X-rays.




Figure S3. Crystal structure of **9** with thermal ellipsoids at 50% probability


Bond precision:	C-C = 0.0034 Å	Wavelength=1.54184	
Cell:	a=17.8847(4)	b=9.00834(19)	c=25.4932(6)
	alpha=90	beta=106.905(2)	gamma=90
Temperature:	293 K		
	Calculated	Reported	
Volume	3929.77(16)	3929.75(15)	
Space group	C 2/c	C 1 2/c 1	
Hall group	-C 2yc	-C 2yc	
Moiety formula	C21 H23 N O4 S	C21 H23 N O4 S	
Sum formula	C21 H23 N O4 S	C21 H23 N O4 S	
Mr	385.46	385.46	
Dx, g cm ⁻³	1.303	1.303	
Z	8	8	
Mu (mm ⁻¹)	1.682	1.682	
F000	1632.0	1632.0	
F000'	1639.34		
h, k, lmax	21, 11, 31	21, 10, 31	
Nref	3777	3716	
Tmin, Tmax	0.817, 0.889	0.966, 1.000	
Tmin'	0.790		
Correction method= # Reported T Limits: Tmin=0.966 Tmax=1.000			
AbsCorr = MULTI-SCAN			
Data completeness=	0.984	Theta(max) = 70.708	
R(reflections)=	0.0490(3116)	wR2(reflections)= 0.1477(3716)	
S =	1.036	Npar= 251	

11.852


8.818
8.797
7.984
7.964
7.841
7.821
7.785
7.766
7.609
7.590
7.569
7.520
7.504
7.483
7.461
7.443
7.423
7.352
7.332
7.301
7.296
7.274
7.256
7.243
7.073
7.054
7.035

2.422

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3a**



194.32

165.97

146.15

140.70

134.84

134.80

134.47

133.53

132.18

131.95

130.40

129.98

128.72

128.48

128.11

127.49

127.41

127.38

126.60

126.17

124.21

122.44

121.23

119.08



77.32

77.00


76.68

21.69

¹³C NMR (100 MHz, CDCl₃) spectra of **3a**



11.334



8.049
8.031

7.213
7.199
7.152


6.679
6.661
6.482
6.426
6.333
6.319
5.981
5.965

3.934

1.565

0.000

¹H NMR (400 MHz, CDCl₃) spectra of **3aa**



1.04

1.01

4.03

5.03

7.04

1.00

2.01

3.00

12.5 12.0 11.5 11.0 10.5 10.0 9.5 9.0 8.5 8.0 7.5 7.0 6.5 6.0 5.5 5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 -0.5

f1 (ppm)

196.27

166.24
166.05

147.64
145.73
142.23




132.40
129.93
128.96
128.89
128.62
128.36
127.48
122.68
120.83
119.69

77.32
77.00
76.68

50.68

21.73


¹³C NMR (100 MHz, CDCl₃) spectra of **3aa**




11.865

8.829
8.808
8.034
7.965
7.946
7.784
7.764
7.664
7.646
7.582
7.562
7.498
7.455
7.438
7.419
7.323
7.315
7.277
7.254
7.245
7.072
7.053
7.034

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3b**





— 194.31

— 165.96

140.75
137.85
134.86
134.72
134.44
133.55
132.06
131.95
130.13
129.80
128.71
128.49
128.09
127.54
127.29
126.78
126.09
124.10
122.43
121.21
119.08


77.32
77.00
76.68

¹³C NMR (100 MHz, CDCl₃) spectra of **3b**




11.845

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3c**

8.823
8.802
7.989
7.970
7.816
7.799
7.761
7.741
7.708
7.690
7.612
7.592
7.573
7.531
7.512
7.495
7.473
7.452
7.433
7.289
7.275
7.256
7.069
7.050
7.031





194.18

165.98

140.76
136.78
134.94
134.43
133.49
133.18
132.00
131.91
130.49
130.29
128.75
128.72
128.53
128.11
127.67
127.41
127.17
125.92
124.07
122.45
121.28
118.92

77.32
77.00
76.68

¹³C NMR (100 MHz, CDCl₃) spectra of **3c**




11.929


8.851
8.830
8.022
8.004
7.797
7.778
7.599
7.580
7.561
7.526
7.509
7.476
7.453
7.315
7.305
7.265
7.254
7.053
7.034
7.015

3.283

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3d**




—194.46

—165.94


140.88
134.99
134.52
133.55
132.02
131.99
130.18
128.76
128.59
128.12
127.66
127.44
126.96
125.62
123.91
122.42
121.18
118.83

77.32
77.00
76.68

—43.27




¹³C NMR (100 MHz, CDCl₃) spectra of **3d**




11.782

1




8.814
8.793
7.978
7.958
7.838
7.818
7.781
7.762
7.631
7.612
7.592
7.530
7.512
7.497
7.472
7.453
7.433
7.358
7.338
7.261
7.259
7.234
7.100
7.081
7.062
7.006
6.984
6.962



2.427

0.000

¹H NMR (400 MHz, CDCl₃) spectra of **3e**



— 194.09

— 165.95
— 163.47
— 161.02



— 146.23

— 140.66
— 134.85
— 134.76
— 134.44
— 133.40
— 131.99
— 130.43
— 129.87
— 129.79
— 129.00
— 128.74
— 128.30
— 128.27
— 127.39
— 126.42
— 124.25
— 122.49
— 121.36
— 119.05
— 115.56
— 115.34

— 77.32
— 77.00
— 76.68

— 21.70

¹³C NMR (100 MHz, CDCl₃) spectra of **3e**




11.764


8.819
8.798
7.974
7.956
7.838
7.818
7.797
7.778
7.648
7.627
7.608
7.515
7.497
7.470
7.460
7.438
7.362
7.342
7.283
7.262
7.230
7.212
7.119
7.101
7.083

2.431

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3f**



—193.97

—165.99

—146.30

—140.71

—134.91

—134.74

—134.45

—133.49

—133.37

—132.01

—130.76

—130.47

—129.44

—128.87

—128.76

—128.68

—127.41

—126.58

—126.35

—124.28

—122.55

—121.45

—119.28



—77.32

—77.00

—76.68

—21.72

¹³C NMR (100 MHz, CDCl₃) spectra of **3f**




11.758


8.819
8.798
7.972
7.953
7.836
7.817
7.800
7.780
7.649
7.630
7.611
7.533
7.514
7.497
7.473
7.459
7.435
7.416
7.359
7.340
7.301
7.286
7.263
7.172
7.153
7.123
7.104
7.085

2.429

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3g**



—193.93

—165.98

—146.32

—140.71

—134.92

—134.71

—134.44

—133.35

—132.02

—131.62

—131.23

—130.47

—129.75

—128.89

—128.76

—127.42

—127.40

—126.62

—126.29

—124.28

—122.56

—121.64

—121.46

—119.26



—77.32

—77.00

—76.68

—21.72

¹³C NMR (100 MHz, CDCl₃) spectra of **3g**




11.725


8.821
8.801
7.966
7.949
7.850
7.832
7.817
7.796
7.653
7.634
7.615
7.568
7.549
7.490
7.471
7.453
7.420
7.401
7.372
7.348
7.130
7.111
7.092


2.434

0.000




¹H NMR (400 MHz, CDCl₃) spectra of **3h**






¹³C NMR (100 MHz, CDCl₃) spectra of **3h**

193.75, 165.98, 146.43, 140.70, 134.97, 134.62, 134.41, 133.27, 132.03, 130.52, 128.77, 128.65, 128.43, 127.45, 127.38, 126.81, 126.31, 125.47, 125.43, 125.40, 125.36, 124.27, 122.57, 121.53, 119.88, 77.32, 77.00, 76.68, 21.73






— 194.41

— 166.01


— 146.09
— 140.67
— 137.32
— 134.89
— 134.74
— 134.49
— 133.56
— 131.93
— 130.38
— 129.98
— 129.21
— 128.71
— 127.94
— 127.44
— 127.36
— 126.61
— 126.15
— 124.37
— 122.48
— 121.26
— 118.84


77.32
77.00
76.68


21.69
21.16




¹³C NMR (100 MHz, CDCl₃) spectra of **3i**







¹³C NMR (100 MHz, CDCl₃) spectra of **3j**




11.858


8.828
8.807
7.997
7.818
7.797
7.751
7.731
7.634
7.615
7.595
7.545
7.528
7.510
7.491
7.472
7.455
7.436
7.430
7.381
7.374
7.353
7.348
7.337
7.316
7.269
7.257
7.250
7.103
7.088
7.066

2.410

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3k**



—194.35

—165.93

—146.16

—140.65

—134.82

—134.75

—134.49

—133.55

—132.34

—131.99

—130.39

—128.76

—127.65

—127.40

—127.34

—126.48

—126.43

—125.59

—124.52

—124.41

—122.68

—122.47

—121.29


—119.01

77.32

77.00


76.68

—21.68




3k

¹³C NMR (100 MHz, CDCl₃) spectra of **3k**



11.662




8.810
8.789
8.022
7.845
7.810
7.790
7.678
7.659
7.639
7.534
7.512
7.493
7.471
7.443
7.407
7.357
7.338
7.319
7.294
7.258
7.210
7.191
7.172
6.967
6.925

2.408

0.000

¹H NMR (400 MHz, CDCl₃) spectra of **31**



193.87

165.89

146.21

140.17

136.98

134.70

134.49

134.42

132.83

132.00

130.57

130.42

128.79

128.64

127.78

127.50

127.39

127.35

127.21

126.54

126.31

125.06

122.70

121.68

118.96

117.49



77.32

77.00


76.68

21.69

^{13}C NMR (100 MHz, CDCl_3) spectra of **31**



11.709




8.792
8.770
7.974
7.955
7.870
7.852
7.653
7.620
7.589
7.554
7.525
7.507
7.480
7.463
7.442
7.380
7.360
7.298
7.293
7.261
7.239
7.220

2.439

0.000

¹H NMR (400 MHz, CDCl₃) spectra of **3m**



— 193.09

— 165.84

— 146.28

— 139.15

— 134.81

— 134.33

— 134.15

— 132.78

— 132.16

— 132.02

— 130.49

— 130.00

— 128.80

— 128.53

— 128.18

— 127.62

— 127.40

— 126.41

— 126.15

— 125.18

— 122.61

— 119.28



— 77.32

— 77.00

— 76.68

— 21.72

¹³C NMR (100 MHz, CDCl₃) spectra of **3m**




11.728


8.739
8.716
7.974
7.956
7.873
7.856
7.788
7.754
7.727
7.632
7.609
7.564
7.524
7.507
7.477
7.461
7.444
7.381
7.363
7.297
7.260
7.235
7.219

2.437

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3n**



192.97

165.81

146.26

139.61

137.21

135.73

134.79

134.12

132.17

131.99

130.49

129.99

128.79

128.53

128.18

127.60

127.39

126.44

126.13

125.41

122.79

119.25


114.69

77.32


77.00

76.68

21.72



¹³C NMR (100 MHz, CDCl₃) spectra of **3n**




11.754

8.695
8.674


7.985
7.965
7.852
7.834
7.505
7.499
7.467
7.450
7.432
7.390
7.364
7.344
7.299
7.265
7.262

2.435
2.241

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3o**



194.39

165.83

146.15

138.31

135.46

134.95

134.63

133.87

132.31

131.97

131.85

130.41

130.03

128.71

128.47

128.13

127.48

127.40

126.84

126.09

124.06

121.16

119.00

77.32



77.00

76.68


21.71

20.65

^{13}C NMR (100 MHz, CDCl_3) spectra of **3o**



11.868





8.795
8.774
8.008
7.994
7.978
7.846
7.829
7.797
7.778
7.616
7.596
7.576
7.504
7.479
7.457
7.361
7.342
7.302
7.296
7.277
7.263
7.258
7.140
7.123
7.102
7.085
7.065
7.047

2.434


0.000

¹H NMR (400 MHz, CDCl₃) spectra of **3p**





¹³C NMR (100 MHz, CDCl₃) spectra of **3p**




11.898


8.794
8.773
7.922
7.907
7.845
7.830
7.805
7.786
7.615
7.597
7.578
7.516
7.483
7.478
7.421
7.406
7.358
7.339
7.303
7.299
7.274
7.263
7.256
7.252
7.089
7.071
7.056


2.429

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3q**





¹³C NMR (100 MHz, CDCl₃) spectra of **3q**

194.41

164.82

146.19

140.58

138.26

134.89

134.83

133.61

132.87

132.15

130.41

130.00

128.97

128.86

128.49

128.12

127.53

127.39

126.47

126.21

124.08

122.63

121.15


119.14

77.32

77.00

76.68

21.69




11.899


8.793
8.772
7.851
7.831
7.805
7.785
7.620
7.597
7.576
7.499
7.477
7.456
7.363
7.345
7.301
7.277
7.260
7.093
7.077
7.057


2.436

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3r**






¹³C NMR (100 MHz, CDCl₃) spectra of **3r**

194.40
164.92
146.19
140.56
134.89
134.83
133.61
133.34
132.15
131.96
130.41
130.01
129.02
128.48
128.12
127.53
127.39
126.80
126.46
126.22
124.08
122.65
121.15
119.15

77.32
77.00
76.68

21.70




11.818


8.818
8.796
7.883
7.863
7.843
7.823
7.776
7.756
7.602
7.582
7.563
7.474
7.469
7.358
7.337
7.299
7.293
7.275
7.260
7.253
7.233
7.059
7.040
7.021


2.430
2.384

0.000




¹H NMR (400 MHz, CDCl₃) spectra of **3s**





¹³C NMR (100 MHz, CDCl₃) spectra of **3s**




11.808

8.810
8.788
7.961
7.939
7.843
7.823
7.778
7.759
7.600
7.581
7.561
7.485
7.470
7.464
7.359
7.339
7.298
7.294
7.279
7.261
7.053
7.034
7.015
6.946
6.924


3.839


2.431

0.000




¹H NMR (400 MHz, CDCl₃) spectra of **3t**





¹³C NMR (100 MHz, CDCl₃) spectra of **3t**




10.761

8.577
8.556
7.843
7.823
7.764
7.745
7.563
7.545
7.524
7.433
7.427
7.373
7.352
7.308
7.294
7.285
7.275
7.261
7.076
7.057
7.038

2.448



2.129

0.000



3u

¹H NMR (400 MHz, CDCl₃) spectra of **3u**



— 193.55

— 169.24

— 146.21

— 140.21

— 134.86

— 134.50

— 132.99

— 132.24

— 130.43

— 130.21

— 128.46

— 128.18

— 127.61

— 127.40

— 126.76

— 126.40

— 124.17

— 122.33

— 121.33

— 119.30


— 77.32

— 77.00


— 76.68

— 25.25


— 21.72



¹³C NMR (100 MHz, CDCl₃) spectra of **3u**






8.535
 7.825
 7.804
 7.678
 7.658
 7.360
 7.339
 7.319
 7.272
 7.257
 7.249
 6.675
 6.524
 6.505
 6.486



2.888
 2.875
 2.427
 0.000

¹H NMR (400 MHz, CDCl₃) spectra of **3v**



— 193.00

— 152.46

— 145.75

135.30

134.75

132.70

130.25

129.97

128.55

127.93

127.22

123.90

118.42

118.30

113.81

110.85


77.32

77.00


76.68

— 29.30


— 21.65



¹³C NMR (100 MHz, CDCl₃) spectra of **3v**



8.056
8.038
8.017
7.911
7.890
7.792
7.720
7.702
7.454
7.436
7.417
7.392
7.372
7.337
7.318
7.299
7.238
7.219
7.201
7.188
7.135
7.116
7.098
7.070
7.051
7.033




3wa

4.759

2.327

0.000

¹H NMR (400 MHz, CDCl₃) spectra of 3wa



1.98
1.99
1.02
2.02
4.05
5.02
2.98

1.98

3.00

9.0
8.5
8.0
7.5
7.0
6.5
6.0
5.5
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
-0.5

f1 (ppm)

—192.06


166.77
165.70

147.91
145.65
138.78
136.50
134.96
134.71
134.20
132.13
129.89
129.83
129.64
129.18
128.75
128.61
128.34
128.28
127.04
125.83
125.08
120.63


77.32
77.00
76.68

—50.78

—21.68



¹³C NMR (100 MHz, CDCl₃) spectra of **3wa**




8.117
8.097
7.954
7.934
7.698
7.680
7.663
7.553
7.535
7.518
7.458
7.439
7.419
7.319
7.299
7.258
7.250
7.230
7.190
7.175
7.159
7.139
7.116
7.096
7.080
7.060


4.692

2.416

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3xa**



190.07


166.62
164.79

149.36
147.09
145.46
137.86
134.83
134.37
134.28
130.96
129.97
129.83
129.74
129.57
128.97
128.94
128.46
128.23
128.08
127.97
125.93
123.43


77.32
77.00
76.68

50.20

21.66



¹³C NMR (100 MHz, CDCl₃) spectra of **3xa**




8.051
8.032
7.679
7.661
7.472
7.456
7.438
7.377
7.358
7.294
7.279
7.264
7.206
7.189
7.164
7.147
7.130


4.798

2.444

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **3ya**



—192.53

—166.63

—147.64

—145.63

—136.39

—134.78

—134.43

—134.18

—129.90

—129.69

—129.44

—129.22

—128.70

—128.60

—128.35

—128.30

77.32


77.00

76.68


—50.63

—21.72

¹³C NMR (100 MHz, CDCl₃) spectra of **3ya**



3ya



8.025
8.007
7.625
7.608
7.424
7.409
7.354
7.335
7.293
7.285
7.281


4.725

3.770
3.753
3.733
3.715


2.422


1.439
1.420

0.000




¹H NMR (400 MHz, CDCl₃) spectra of **5a**





¹³C NMR (100 MHz, CDCl₃) spectra of **5a**




8.148
8.130
7.657
7.638
7.623
7.608
7.574
7.556
7.537
7.426
7.410
7.314
7.286
7.259

4.738


3.776
3.758
3.739
3.722


1.443
1.425

0.000




¹H NMR (400 MHz, CDCl₃) spectra of **5b**





¹³C NMR (100 MHz, CDCl₃) spectra of **5b**




8.086
8.068
7.634
7.616
7.429
7.413
7.322
7.289
7.266
7.017
6.999

4.726


3.864
3.773
3.755
3.736
3.719


1.446
1.427

0.000




¹H NMR (400 MHz, CDCl₃) spectra of **5c**





¹³C NMR (100 MHz, CDCl₃) spectra of **5c**




7.933
7.915
7.621
7.603
7.545
7.528
7.356
7.339
7.250
7.231
7.220
7.216
7.209

4.649

3.709
3.689
3.670
3.651


1.372
1.354

0.000



5d

¹H NMR (400 MHz, CDCl₃) spectra of **5d**




—169.79
—163.47
—151.12
—138.86
—137.47
—134.12
—132.44
—129.54
—129.25
—127.41
—126.82
—123.56
—120.93


77.32
77.00
76.68

—49.48
—42.37

—15.45



¹³C NMR (100 MHz, CDCl₃) spectra of **5d**



7.946
7.925
7.485
7.473
7.460
7.283
7.265
7.066
7.045
6.948
6.926
6.905


4.641

3.692
3.675
3.656
3.638


2.353


1.364
1.348

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **5e**





168.74
163.46
163.26
161.01
153.52
153.44
145.09
138.44
135.62
130.37
130.35
129.78
128.07
121.84
121.75
114.45
114.22
111.77
111.53

77.32
77.00
76.68


49.31

42.44

21.66

15.45

¹³C NMR (100 MHz, CDCl₃) spectra of **5e**



8.027
8.009
7.541
7.522
7.403
7.366
7.347
7.302
7.282
7.265


4.725

3.781
3.762
3.743
3.725


2.433


1.446
1.427

0.000




¹H NMR (400 MHz, CDCl₃) spectra of **5f**





¹³C NMR (100 MHz, CDCl₃) spectra of **5f**



7.950
7.929
7.483
7.415
7.395
7.378
7.375
7.358
7.354
7.290
7.270


4.642

3.702
3.683
3.664
3.645


2.357


1.368
1.349

0.000




¹H NMR (400 MHz, CDCl₃) spectra of **5g**





5g

^{13}C NMR (100 MHz, CDCl_3) spectra of **5g**



7.957
7.936
7.645
7.626
7.583
7.524
7.504
7.275


4.699

3.785
3.766
3.747
3.728



2.358


1.415
1.395

0.000




¹H NMR (400 MHz, CDCl₃) spectra of 5h





¹³C NMR (100 MHz, CDCl₃) spectra of **5h**



7.945
7.927

7.447
7.294
7.275
7.164


4.666

3.849
3.831
3.812
3.794

2.361


1.461
1.442

0.000



5i

¹H NMR (400 MHz, CDCl₃) spectra of **5i**



— 171.26

— 162.57

145.80

145.28

137.50

137.29

135.32

134.49

130.72

129.81

128.05

127.03

— 119.97

77.32

77.00


76.68

— 49.28

— 42.68


— 21.67

— 13.65



5i

¹³C NMR (100 MHz, CDCl₃) spectra of **5i**



8.021
8.002

7.497
7.478
7.349
7.330
7.228
7.112
7.093


4.704

3.726
3.708
3.689
3.670


2.420
2.385


1.421
1.402

0.000





¹H NMR (400 MHz, CDCl₃) spectra of **5j**







¹³C NMR (100 MHz, CDCl₃) spectra of **5j**







^{13}C NMR (100 MHz, CDCl_3) spectra of **5k**



8.024
8.005
7.622
7.605
7.418
7.402
7.352
7.333
7.288
7.275
7.261
7.217


4.764
4.750

3.725
3.685
3.671

2.420
2.087
2.053
2.036
2.004
1.832
1.814
1.796
1.779
1.743


0.923
0.905
0.887


0.000




5I

¹H NMR (400 MHz, CDCl₃) spectra of **5I**





¹³C NMR (100 MHz, CDCl₃) spectra of **5I**



8.086
8.066
7.632
7.614
7.426
7.409
7.318
7.300
7.283
7.266
7.017
6.998


4.814
4.766
4.752
4.703

3.863
3.708
3.692
3.676

2.096
2.061
2.044
2.026
1.838
1.821
1.803
1.767

0.933
0.914
0.896

0.000



5m

¹H NMR (400 MHz, CDCl₃) spectra of **5m**


2.00
1.00
1.02
2.03
2.01

2.02

3.00
1.00

1.02
1.00

3.04



— 168.12
— 163.91
— 163.53

— 149.46

— 139.94
— 134.91
— 130.33
— 130.04
— 127.34
— 126.59
— 123.76
— 120.90


— 114.29

— 77.32
— 77.00
— 76.68


— 55.66
— 50.14
— 49.30

— 23.71

— 11.07



¹³C NMR (100 MHz, CDCl₃) spectra of **5m**



8.029
8.010
7.629
7.612
7.420
7.403
7.357
7.337
7.294
7.278
7.261


4.812
4.764
4.745
4.696

3.729
3.712
3.696

2.425
2.007
1.974
1.953
1.940
1.736
1.716
1.683


1.308
0.942
0.883
0.831


0.000




5n

¹H NMR (400 MHz, CDCl₃) spectra of 5n





¹³C NMR (100 MHz, CDCl₃) spectra of **5n**




7.930
7.914
7.538
7.520
7.299
7.265
7.246
7.210
7.191
7.180
7.151
7.130
7.053
7.038

4.599

3.672
3.633
3.585

2.568
2.553
2.536
2.340
1.958
1.933
1.910
1.897
1.884
1.734
1.718
1.699
1.684
1.666
1.649
1.612
1.534
1.479

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **5o**




1.92
0.97
8.03
2.03

1.96

0.94

1.95
3.00

1.05
1.02
2.03



168.11
163.39
149.49
145.01
141.25
139.80
135.59
134.74
129.74
128.48
128.32
128.01
127.37
126.62
126.11
123.77
120.95


77.32
77.00
76.68

50.10
47.86


35.68

29.85
28.38

21.64



¹³C NMR (100 MHz, CDCl₃) spectra of **5o**



8.087
8.077
8.016
8.002


7.352
7.337
7.204
7.194
7.140

4.569
4.521
4.460
4.412

3.014
2.968
2.888
2.872
2.710
2.668
2.651
2.426


1.254
1.215
1.205
1.193


— 0.000



5pa


¹H NMR (400 MHz, CDCl₃) spectra of **5pa**





5pa

¹³C NMR (100 MHz, CDCl₃) spectra of **5pa**



7.957
7.936

7.327
7.307
7.288
7.190
7.171
7.116
7.098
7.037
7.005
6.987

5.848
5.817
5.788
5.770


4.626

2.798
2.781
2.765
2.619
2.604
2.587
2.569
2.430

2.071
2.036
1.993
1.913


0.961
0.880
0.830


0.000



5qa


¹H NMR (400 MHz, CDCl₃) spectra of **5qa**





0.000


¹H NMR (400 MHz, CDCl₃) spectra of **6**



6

11.740

8.908
8.723
8.707
7.989
7.974
7.812
7.795
7.558
7.543
7.523
7.501
7.486
7.464
7.444
7.430
7.367
7.353
7.315
7.298
7.278
7.264
7.258
7.241
7.226
7.052
7.040
7.017
6.990
6.910
6.905
6.872




— 194.48


— 166.21

— 139.71
— 134.43
— 134.30
— 133.36
— 133.15
— 131.95
— 128.73
— 128.32
— 128.25
— 127.45
— 127.12
— 126.94
— 126.45
— 126.29
— 122.69
— 122.43
— 121.45
— 118.79

— 77.32
— 77.00
— 76.68



¹³C NMR (100 MHz, CDCl₃) spectra of **6**




7.753
7.732
7.300
7.284
7.262
7.240
7.220
7.182
7.163
7.114
6.863
6.590

5.839



4.250

2.369

0.000



¹H NMR (400 MHz, CDCl₃) spectra of **7**




145.85
145.17
139.25
130.03
129.22
129.08
128.54
128.26
127.55
127.26
127.04
126.99
126.98
118.62
116.78
111.58

77.32
77.00
76.68

68.16


47.68

21.59



¹³C NMR (100 MHz, CDCl₃) spectra of **7**

139.25
135.76
133.22
130.03
129.22
129.08
128.54
128.26
127.55
127.26
127.04
126.99
125.98
119.98
118.62
116.78
111.58



7.734
7.714
7.352
7.332
7.312
7.258
7.239
7.219
7.191
7.173

5.323
5.284
5.272

4.626
4.594
4.568
4.536


4.104
4.092
4.069
4.058
3.805
3.787
3.771
3.753

3.341
3.329
3.316

2.385
2.012
1.993
1.982
1.965
1.947
1.742
1.726
1.708
1.674


0.517
0.498
0.480

0.000



8

¹H NMR (400 MHz, CDCl₃) spectra of **8**



146.33
143.51
143.33
142.00
139.99
136.70

129.67
127.09
126.52
125.36
123.00
119.40

77.32
77.00
76.68

56.31


50.54

38.97


22.18
21.47

8.74

¹³C NMR (100 MHz, CDCl₃) spectra of 8



8



7.764
7.744
7.503
7.485
7.336
7.317
7.299
7.277
7.258
7.222
7.204
7.186



5.121
5.106
5.092

4.224
4.079
4.060
4.044
4.026
3.958
3.947
3.924
3.912
3.890
3.703

2.548
2.529
2.510
2.491
2.396

1.159
1.140
1.121

— 0.000



9



¹H NMR (400 MHz, CDCl₃) spectra of **9**


2.00
1.01
4.06
1.02


1.00

0.99
1.01
1.06
3.01

2.04
3.00

3.03





¹³C NMR (100 MHz, CDCl₃) spectra of **9**

171.36
146.64
144.17
143.40
140.11
136.76
132.48
129.60
127.69
127.15
125.83
123.87
119.66

77.32
77.00
76.68

55.44
52.55

39.94

21.48
18.59
13.42

